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ABSTRACT:
One of the current challenges in the fight against cancer is to find anti
cancer treatments that specifically target cancerous cells, while leaving normal
cells unharmed. Apoptosis, or programmed cell death, is a non-traumatic,
physiological process by which cells that are no longer needed or are potentially
harmful can be removed from the system. Recently, anti-cancer research has
focused on targeting the components of biochemical pathways that can induce
apoptosis specifically in cancerous cells. The search for cancer-specific drugs
has led some researchers to investigate the potential anti-cancer activity of
natural compounds.

Pancratistatin (PST) is a natural compound that was

isolated from the spider lily Pancratium littorale and has shown to exhibit
antineoplastic activity. The specificity of PST to cancer cells and the mechanism
of its action remain unknown.

In this study, we provide a detailed look at the

effect of PST treatment on several types of cancerous and normal cells.

Our

results indicate that PST induced apoptosis selectively and effectively in cancer
cells, while normal cells were not affected. In this study we have found that PST
activates the intrinsic apoptotic pathway in cancerous cells and our results
indicate that the mitochondria may be the site of action of PST in cancer cells, as
experiments using isolated mitochondria have shown that only the mitochondria
isolated from cancerous cells are vulnerable to PST treatment. This study has
demonstrated

the

novel

anti-cancer

potential

of the

natural

compound

Pancratistatin and provided insight into a possible biochemical target available
only in cancerous mitochondria that may allow us to specifically target cancer.
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CHAPTER 1: INTRODUCTION
1.1 Cancer
C a n ce r, is one of today’s largest killers, despite improved cancer
treatments and an increased understanding about the causes of the disease. In
Canada, there were approximately 149,000 new cases of cancer and 69,500
cancer-related deaths in 2005. It is estimated that one in every four Canadians
will develop cancer during their lifetime. In addition, cancer is the leading cause
of premature death in Canada (Canadian Cancer Society 2005).
Cancer is a general term for approximately 100 diseases that share
several common characteristics. The development of cancer can be linked to
uncontrolled cellular division and the capacity of these cells to invade other
tissues: by direct growth into adjacent tissue (invasion) or by movement to
remote tissues (metastasis) (Kleinsmith 2006, pp. 19 - 129).

As the disease

progresses, these excessive cells begin to inhibit the normal functions of the
body and, if left untreated, cancer leads to death.

1.1.1 How cancer arises

Cancer cells are characterized by accelerated growth and a disrupted
apoptotic (cell suicide) mechanism.

This loss of control is induced by DNA

mutations in the genes that encode proteins controlling cell division and/or cell
death (Tannock et at. 2005, pp. 91 - 184, Kleinsmith 2006, p. 19 - 129). Under
normal conditions, the body has mechanisms to deal with DNA mutations, but
cancer-causing mutations cause lack of function in proteins that would monitor

1
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cell division and apoptosis.

These damages result in cells that can bypass

normal cell cycle checkpoints.

Thus, mutations are allowed to accumulate

beyond the ability of cellular repair mechanisms (Osborne et at. 2004).
Several key genetic mutations are required to transform a normal cell into
a malignant or cancerous cell. These mutations are caused by any number of
factors related to the environment, lifestyle, and heredity of the individual. There
are many factors associated with an increased risk of developing cancer:

an

estimated 80% of all cancers can be linked to tobacco products, dietary factors,
or exposure to carcinogens (Ames etal. 1995).
Cancer-causing genetic mutations result in the formation of oncogenes or
the malfunction of tumor suppressor genes (Osborne et at. 2004, Weinberg
1996). Proto-oncogenes are often involved in growth signaling and anti-apoptotic
pathways. When these genes develop mutations and become oncogenes, they
preserve their functionality, but no longer respond to normal regulatory signals,
leading to excessive cell division. Tumor suppressor genes code for the proteins
that inhibit cell division if the conditions for growth are not met. Mutation of tumor
suppressor genes results in cancer cells without functional apoptotic machinery
and a prolonged lifespan (Chabner and Roberts 2005, Weinberg 1996).

2
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1.1.2 Current anti-cancer therapies
The choice of cancer therapy is dependent upon the location of the
malignancy anp the stage at which the cancer is detected. The overall goal of
each and every cancer treatment is to have complete removal of the tumor, while
causing minimum damage to the rest of the body.

Regrettably, many current

therapies do not meet this requirement.
There are two main types of anti-cancer therapies: local and systematic.
Local therapies, such as surgery and radiation, work by directly targeting the
affected area and are frequently used in combination with supplementary
treatments. Surgery involves the removal of the cancerous growth and possibly
the adjacent tissue. Unfortunately, this is often not enough: one missed, cell can
result in the relapse of the tumor.
Approximately 70% of diagnosed cancer patients will receive radiation
therapy (Martin 2001). Radiation induces apoptosis in cancerous cells by
focusing a beam of ionizing radiation (IR) at the specific tumor.

This causes

interference with cell division by introducing oxidative stress and DNA injury
(Jeremic 2004).

While cancerous cells are more susceptible to IR, radiation

therapy often leads to harsh side effects due to the large number of normal cells
that acquire DNA damage and oxidative stress (McLachlan-Burgess et al. 2006).
Additionally, DNA damage that goes un-repaired in normal cells may lead to the
formation of secondary cancers (Zhang et al. 2001).
Systematic therapies, such as chemotherapy, hormone therapy, and
immunotherapy, work by introducing an anti-cancer agent to the entire system or

3
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body. Chemotherapeutic agents such as DNA-targeting agents (topoisomerase
inhibitors) and microtubule-targeting agents (taxanes) induce apoptosis in cancer
cells by targeting fast-dividing cells.

Unfortunately, these targets are found in

both cancerous and dividing healthy cells resulting in harsh side effects (Thatte
etal. 2000).
Hormone therapies work by removing or blocking the action of particular
hormone receptors that stimulate the growth of tumors. Certain types of breast,
prostate, and thyroid cancers can be treated using hormone therapies (Tannock
et al. 2005, pp. 91 -184, Kleinsmith 2006, pp. 19 - 129). Anti-estrogens, such as
tamoxifen, compete with estrogens for binding to the estrogen receptor (ER) on
breast cancer cells and thereby block estrogen’s ability to activate cell division of
these cells.
treatment:

Unfortunately, there are side effects associated with anti-estrogen
long-term use of tamoxifen can lead to increased incidence of

endometrial cancer, thromboembolic events, and the development of resistance
(Baum 2005).
Immunotherapy makes use of immune mechanisms against tumors and
therefore, can be used to treat various forms of cancer including leukemia and
breast cancer (Kim 2005). The agents are monoclonal antibodies directed
against proteins characteristic to the cells of the cancer in question or cytokines
that modulate the immune system’s response. For example, HER-2 is a growth
promoting protein that is over expressed on the surface of many breast cancers
(Duffy 2005). Trastuzumab, a therapeutic monoclonal antibody, binds to HER-2
which leads to the inhibition of HER-2 and therefore, the growth of the cancer.

4
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This treatment inhibits cell cycle progression as a result of p27 induction and
causes inhibition of angiogenesis and induction of an immune response (Duffy
2005).

HowQver, the benefits of trastuzumab therapy may have limited

applications. Research has indicated that the response-rate from this treatment
is limited in extent and duration even when the levels of HER-2 over-expression
are high (Albanell and Baselga 2001).
Although there has been some success from targeting the DNA or over
expressed receptors in cancer cells, resistance to treatment is often a problem.
Additionally, the harsh side effects that result from the death of normal cells and
the appearance of secondary cancers make these treatments risky and often
unbearable to the patients.
The current challenge in cancer therapy is to find anti-cancer treatments
that specifically target cancerous cells, while leaving normal cells unscathed.
The main problem is that, unlike foreign species such as bacterial or fungal
pathogens, cancer cells are the organisms own cells. For example, antibiotics
make use of the cell wall that is present in bacteria, but not in mammalian cells.
While

many current treatments,

such

as chemotherapeutic

agents

and

radiotherapies, cause DNA-damage in cancerous cells in order to induce cell
death (Hui and Kavanagh 2003), these non-specific genotoxic treatments cause
an excessive number of normal cells to be killed during therapy leading to harsh
side effects or, even worse, DNA mutations leading to the formation of secondary
cancers (Boose and Stopper 2000). In order to find cancer specific therapies, we
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must identify differences between normal and cancerous cells and find a way to
target theses differences.

1.2 Apoptosis
1.2.1 Apoptosis versus necrosis
In 1972, research by Kerr et al. uncovered two types of cell death:
apoptosis, or physiological cell death, and necrosis, pathological cell death (Kerr
etal. 1972).
Necrotic cell death is often caused by an external physical or chemical
factor such as physical damage, injury, extreme heat or pressure, or toxic agents
(Szabo 2005). This type of cell death is often sudden and results in uncontrolled
biochemical changes such as random DNA degradation and proteolysis of
proteins.

Morphologically, necrosis induces swelling of cellular organelles, an

increase in the cell’s volume, and the eventual rupture of the cellular membrane.
When the cells rupture, the cellular contents, including any un-degraded DNA
and proteins, are released into the intracellular surroundings (Szabo 2005). This
results in the activation of macrophages and other immune cells (Duke et al.
1996). This uncontrolled cell death results in inflammation of the affected area
and potential damage to surrounding cells (Haslett 1992).
Apoptosis, on the other hand, is a non-traumatic, controlled form of
physiological cell death.

The apoptotic pathway can be induced by several

physiological factors such as receptor activation, growth factor deprivation, DNA
damage, oxidative stress, and chemotherapeutic drugs (Hickey et al. 2001).
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Once a cell is committed to apoptosis, the biochemical changes result in
systematic

DNA

fragmentation

into

high

molecular

weight

and/or

oligonucleosorpal fragments, chromatin condensation, overall cell shrinkage,
membrane blebbing and finally the formation of apoptotic bodies (Duke et al.
1996).

Once these physiological changes take place, the apoptotic bodies are

safely removed from the area by phagocytosis (Pandey et al. 2000, Green and
Reed 1998).

Because the plasma membrane remains intact during this cell

disposal, the organism is able to rid itself of apoptotic cells without inflammation
or damage to surrounding cells.
Apoptotic cells can be detected by visualizing morphological features such
as cell shrinkage, nuclear condensation and membrane blebbing (Jaattela 2002).
At the microscopic level, cells appear withered and shrunken, and do not adhere
to neighbouring cells. In addition, fluorescent nuclear stains, such as Hoechst,
allow visualization of nuclear condensation under the microscope.

Several

biochemical characteristics can also distinguish apoptotic cells. These include
DNA degradation, proteolysis leading to the activation of caspases, and the
alteration in phospholipid organization leading to the exposure of phosphatidyl
serine on the cell surface. These biochemical changes can be observed using
several assays.

For example, the “membrane flipping” of phosphatidyl serine

can be visualized using the fluorescent probe, annexin V, which binds to the now
exposed phosphatidyl serine.
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1.2.2 Apoptosis in the cell and the organism
In living organisms, apoptosis is an important physiological process that is
required for normal development, tissue homeostasis, and tissue turnover at the
end of an immune response (Ashkenazi and Dixit 1998). Apoptosis acts to
remove cells that are no longer needed or are potentially harmful (Kerr et al.
1972, Green and Reed 1998, Corcoran et al. 1994). Dysfunction in the apoptotic
mechanism can lead to a variety of pathological conditions.

Autoimmune

diseases, such as AIDS, and neurodegenerative diseases including stroke,
Parkinson’s disease, and Alzheimer’s disease arise because of excessive cell
death. On the other hand, the lack of cell death can lead to cancer. Apoptosis
works to remove cells that have accumulated dangerous mutations and, if the
apoptotic machinery fails, uncontrolled proliferation and a resistance to apoptosis
can result in the formation of cancer (Debatin 2004).

1.2.3 The biochemical mechanism of apoptosis
Apoptosis is a highly orchestrated, genetically regulated, cellular process
controlled by the ratio of pro-apoptotic to anti-apoptotic factors. Because of the
involvement of apoptosis in many pathological conditions, recent research has
focused on gaining a better understanding of the biochemical mechanism of
apoptosis. Many factors involved in the initiation and execution of apoptosis in
the cell have been identified.
There are the two major pathways that have been identified: the extrinsic
pathway and the intrinsic mediated pathway.
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1.2.4 The intrinsic pathway of apoptosis
Radiation, chemotherapy, oxidative stress and DNA damaging agents
induce apoptosjs through the intrinsic pathway (Kroemer and Reed 2000). The
intrinsic pathway of apoptosis centers on the permeablization of the mitochondria
and the release of pro-apoptotic proteins (figure 1-1). Apoptosis is initiated by
the activation of pro-apoptotic proteins in response to internal signalling.

The

Bcl-2 family of proteins play a key role in the intrinsic pathway of apoptosis. While
the anti-apoptotic members of the Bcl-2 family such as Bcl-2 work to stabilize the
mitochondria and inhibit the function of pro-apoptotic proteins, the pro-apoptotic
proteins, such as BAX (Bcl-2 associated protein), facilitate the permeablization of
the mitochondrial membrane and the opening of the permeability transition pore
(PTP) (Reed 2000).

Opening of the PTP leads to the collapse of the

mitochondrial potential and release of the pro-apoptotic proteins cytochrome c
and apoptosis inducing factor (AIF) (Green and Reed 1998).
Once out of the mitochondria, cytochrome c forms the apoptosome by
binding to apoptosis activating factor (APAF-1) and caspase-9 in the presence of
ATP (Ashkenazi and Dixit 1998).

The formation of the apoptosome, and

therefore the activation of caspase-9, leads to cleavage and activation of
caspase-3, a key effector asparate-specific cysteinyl protease (caspase). This
induces proteolysis of several proteins including inhibitor of caspase-activated
DNase (ICAD). Proteolysis of ICAD results in the translocation of caspaseactivated DNase (CAD) to the nucleus, where it degrades the DNA (Li et at.
1997).

9
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Figure 1-1: The intrinsic pathway of apoptosis
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Figure 1-1: The intrinsic pathway of apoptosis
In the intrinsic pathway of apoptosis, permeablization of the mitochondrial membrane by proapoptotic proteins leads to the release of cytochrome c, which in turn forms the apoptosome,
activates caspase-9, and leads to the activation of caspase-3. Simultaneously, AIF is released
and trans-locates to the nucleus, where it induces DNA fragmentation.
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AIF, on the other hand, does not require any cytosolic cascade in order
to induce apoptosis. AIF is protein that is located within the intermembrane of
the mitochondria and acts as a bifunctional protein with both an electron
acceptor/donor (oxidoreductase) function and an apoptogenic function (Susin et
al. 1999). During mitochondrial membrane permeablization, AIF is released from
the mitochondria and the now free AIF proteins trans-locate to the nuclei.
Although the exact mechanism of AIF-induced apoptosis is unknown, AIF
proteins bind to DNA in order to induce chromatin condensation and DNA
fragmentation, possibly by the recruitment of nucleases (Susin et al. 1999) and,
therefore, can induce apoptosis in a caspase-independent fashion.

1.2.5 The extrinsic pathway of apoptosis
The best characterized apoptotic pathway is the extrinsic pathway. Here,
death receptors that are members of the TNF (tumor necrosis factor) receptor
family such as the Fas, TNF and TRAIL (TNF related apoptosis-inducing ligand)
receptors are activated by the binding of specific ligands or certain toxins (figure
1-2) (Degterev et al. 2003). This results in the recruitment of various proteins,
including FADD and caspase-8, and the formation of the death inducing signaling
complex (DISC) (Ashkenzai et al. 1998).

This leads to the activation of the

initiator caspase, caspase-8, that further activates the effector caspases
including caspase-3, and thereby leads to DNA fragmentation and apoptosis
(Ashkenazi and Dixit 1998).
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Figure 1-2: The extrinsic pathway of apoptosis
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Figure 1-2: The extrinsic pathway of apoptosis
In the extrinsic pathway of apoptosis, the death receptors are activated by ligand binding, which
leads to the formation of DISC (death inducing signaling complex) and the activation of caspase8. Active caspase-8 causes the activation of caspase-3 and the formation of t-Bid, both of which
lead to apoptosis.
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The extrinsic pathway is also connected to the internal pathway of
apoptosis. Active caspase-8 can also cleave Bid, producing two fragments. One
of the two fragments, truncated-Bid (t-Bid) trans-locates to the mitochondria and
interacts with other pro-apoptotic proteins, including BAX, leading to the collapse
of the mitochondrial membrane potential. Recent research has shown that t-Bid
may form selective ion-channels similar to BAX (Chou et al. 1999, McDonnell et
al. 1999, Korsmeyer etal. 2000).

1.2.6 The role of mitochondria in apoptosis
In addition to being the energy producers of the cell, the mitochondria play
an integral part in the apoptotic machinery of the cell. During electron transport,
protons are pumped from the mitochondrial matrix into the intermembrane space,
resulting in the formation of an electron gradient across the inner mitochondria
membrane, referred to as mitochondrial membrane potential.

Research has

shown that maintenance of ATP production (Leist and Nicotera 1997), release of
caspase activators (cytochrome c) and caspase-independent death effectors
(AIF) from the inter-membrane space into the cytosol, and control over the loss of
essential mitochondrial functions (Green and Kroemer 2004, Yuan et al. 2001
Kroemerand Reed 2000, Vayssiere e ta l. 1994, Zoratti and Szabo 1995) all play
a key role in mitochondrial controlled apoptosis.

While it is accepted that

collapse of the mitochondrial membrane potential leads to the release of proapoptotic proteins, the mechanism by which this occurs is not fully understood.
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There are two extensively researched mechanisms that can lead to
mitochondrial membrane permeablization (MMP).

In one mechanism, the pro-

apoptotic members of Bcl-2 family, such as BAX and Bid, act on the outer
mitochondrial membrane to form channels that allow the release of cytochrome c
(figure 1-3a) (Green and Kroemer 2004).

The anti-apoptotic Bcl-2 family of

proteins, Bcl-2 and Bcl-XL, work by stabilizing the mitochondrial membrane
potential or binding with the pro-apoptotic Bcl-2 family of proteins such as BAX in
order to inhibit their function (Green and Kroemer 2004, Zou et al. 1999, Li et al.
2003, Zou etal. 1997).
The second MMP mechanism involves the formation of the mitochondrial
permeability transition pore (PTP) that results in the swelling and eventual
disruption of the outer mitochondrial

membrane

(Orrenius 2004).

The

mitochondrial PTP is a large multi-protein complex that spans the inner and outer
mitochondrial membranes (figure 1-3b), forming a channel connecting the
mitochondrial matrix to the cytosol (Harris and Thompson 2000, Zoratti and
Szabo 1995). As seen in figure 1-3b, the PTP includes the voltage dependent
anionic

channel

(VDAC),

adenosine

nucleotide

transporter

(ANT),

the

benzodiazapine receptor, hexokinase (HK), creatine kinase (CK) and cyclophilin
D (Harris an Thompson 2000, Zoratti and Szabo 1995).

Many events are

thought to trigger the opening of the PTP including the binding of afore
mentioned proteins, such as BAX, which stimulate a change in the mitochondrial
membrane potential (AvFm).

This can be caused by partial failure of the

mitochondrial respiratory complexes and an increase in the intra-mitochondrial
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Figure 1-3a: Mitochondrial membrane permeablization:
formation of BAX/Bak pores
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Figure 1-3a: Mitochondrial membrane permeablization: formation of BAX/Bak pores
Upon induction of apoptosis, BAX and Bak migrate to the mitochondria where they act to form a
pore in the outer mitochondrial membrane. The formation of this pore leads to the release of
cytochrome c (shown here) and other pro-apoptotic factors.

Figure 1-3b: Mitochondrial membrane permeablization:
opening of the permeability transition pore
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Figure 1-3b: Mitochondrial membrane permeablization: opening of the permeability
transition pore
Upon induction of apoptosis, BAX trans-locates to the mitochondria, where it leads to the
opening of the PTP. Rapid in flow of fluid leads to swelling of the mitochondrial matrix and
rupture of the outer mitochondrial membrane.
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levels of Ca+2 and reactive oxygen species (ROS) in the mitochondrial matrix
(Chernyak and Bernardi 1996). These factors either individually or together can
produce a decrease in mitochondrial membrane potential (Kroemer 2003, Richter
1993). Binding of Bcl-2 can lead to the closure of the PTP (Kroemer and Reed
2000).
In addition to the release of pro-apoptotic proteins (such as cytochrome c
and AIF), mitochondrial membrane permeablization causes mitochondrial
dysfunction and the release of ROS into the cytoplasm. This has been found to
be a sufficient trigger of apoptosis or necrosis, even in cancer cells that are
resistant to apoptotic signals (Kroemer 2003).

1.2.7 The Bcl-2 family of proteins
The Bcl-2 family of proteins are essential to the regulation of apoptosis.
There are approximately 15 mammalian family members of the Bcl-2 group of
proteins and they can be divided into three main categories:

the Bcl-2 pro

survival sub-group which includes Bcl-2, Bcl-XL, Bcl-W, Mcl-1 and A1; the BAX
pro-apoptotic sub-group including BAX, Bak and Bok; and the BH3 pro-apoptotic
subgroup which includes Bad, Bid, Bik, Hrk, BNIP3 and BimL.
Both the anti- and pro-apoptotic members of the Bcl-2 family share four
conserved motifs (BH1 - BH4) (Hunter et al. 1996, Chinnadurai and Lutz 1995).
While Bcl-2 has all four of the BH motifs, all of the anti-apoptotic members
contain at least BH1 and BH2. The members of the BAX pro-apoptotic family
contain BH1, 2 and 3. The BH3 subgroup contains only the BH3 domain. This
homology allows for interaction between the pro- and anti-apoptotic Bcl-2
16
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members: hetero- and horno-dimerization allows the levels of Bcl-2 proteins to
precisely regulate apoptosis (Sattler et al. 1997). For example, apoptotic stimuli
activate the prg-apoptotic protein BAX which trans-locate from the cytoplasm to
the

mitochondria,

homo-dimerizes,

and

then

oligomerizes

within

the

mitochondrial membranes to induce mitochondrial membrane potential collapse
(Leist and Jaattela 2001, Gross et al. 1999, Goping et al. 1998). Bcl-2 inhibits the
trans-location and homo-dimerization of BAX by the formation of Bcl-2/BAX
hetero-dimers (Benedict etal. 2000).

1.2.8 The caspases
The caspases, or cysteine aspartyl-specific proteases, are a class of
intracellular cysteine proteases associated with classical apoptosis and can be
activated via either intrinsic or extrinsic pathways (Thornberry and Lazebnik
1998, Reed 2000).

Caspases work using nucleophilic cysteine residues to

enzymatically cleave its substrate’s peptide bonds on the carboxyl side of
aspartic acid residues (Earnshaw et al. 1999).

Caspases themselves require

proteolytic processing between domains in order to form an active enzyme.
At least 14 different caspases have been identified in mammals. These
can be divided into two major categories:

initiator and effector caspases.

Initiator caspases, which are activated just after the first apoptotic events, include
caspase-2, 8, 9 and 10. The initiator caspase are responsible for cleavage and
activation of the effector caspases (3, 6, and 7). These enzymes then cleave,
degrade or activate other cellular proteins to induce apoptosis (Macfarlane et al.
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1997, Casciola-Rosen et al. 1996). For example, one of the important roles of
effector caspases is to deactivate anti-apoptotic proteins, such as ICAD, that
protect the cells from apoptosis (Enari et al. 1998, Liu et al. 1997).

1.3 Apoptosis and cancer
Dysfunction in the control of apoptosis is responsible for development of
several diseases:

excessive cell death can result in autoimmune diseases,

neurodegenerative disorders, or acquired immune deficiency and a disruption in
a cell’s ability to undergo apoptosis can lead cancer (Kazi et al. 2004, Reed
1996).

As our understanding of the apoptotic pathway has increased, anti

cancer researchers have focused more and more on inducing apoptosis in
cancer cells (Hu et al. 2003).
In order to kill cancer cells, we must find a way to specifically target
cancerous cells, while leaving normal healthy cells unharmed. The challenge in
this task stems from the fact that cancerous cells are the patients’ own cells and
finding a suitable target in cancerous cells has proved difficult.

As previously

discussed, some current therapies attempt to specifically target cancerous cells,
but the applications of these therapies are often limited.
Recently, cancer cells’ mitochondria have provided a novel and exciting
research focus in anti-cancer development.

Studies have found differences

between the mitochondria of cancerous and non-cancerous cells (Don and Hogg
2004, Fantin and Leder 2004). These genetic, molecular, and biochemical
differences may allow us to specifically target the mitochondria of cancerous cells
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and, thus, activate their apoptotic pathway (Modica-Napolitano and Singh. 2002,
2004).
Research has uncovered that cancerous mitochondria have an increased
mitochondrial membrane potential (ATm) (Modica-Napolitano and Singh. 2002,
2004). The lipophilic cation Rh 123 has been found to have significantly higher
uptake by cancerous mitochondria and that the differential A'Fm may be the
reason for this phenomenon (Modica-Napolitano and Singh. 2002).

In addition,

research indicates that selective mitochondrial toxicity and apoptosis results from
this up-take (Modica-Napolitano and Singh. 2002, 2004).
Researchers have discovered that cancerous cells have an altered
metabolism and the mitochondrial differences in cancerous cells are either
directly or indirectly involved in many aspects of this altered metabolism (ModicaNapolitano and Singh. 2002).

For example, the “Warburg phenomenon” is an

increased reliance of cancerous cells on anaerobic metabolism (Green and
Kroemer 2004). Because cancer cells do not rely on functional mitochondria for
their energy needs, the survival of these cells is independent of mitochondrial
dysfunction.
Additional mitochondrial differences have also been observed.

Cancer

cells divide at an extremely fast rate; therefore, these cells may not take the time
to properly prepare every component required for cell division.

Many types of

cancer cells have differences in the number, size, and shape of their
mitochondria relative to their normal counterparts (Modica-Napolitano and Singh.
2002, 2004) and mitochondrial DNA mutations are common among cancer cells
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(Polyak et al. 1998, Sugiura et al. 2004).

Furthermore, the mitochondria of

cancerous cells have been found to possess inner and/or outer membranes with
altered molecular composition (Villa and Doglia 2004).

By targeting these

mitochondrial abnormalities, it may be possible to specifically induce apoptosis in
cancerous cells.
Although DNA mutations leave cancer cells resistant to apoptosis, loss of
mitochondrial membrane potential, and therefore mitochondrial function, alone is
a sufficient trigger of apoptosis or necrosis, even in cancer cells due to the
release of pro-apoptotic proteins (Kroemer 2003).

If an anti-cancer agent can

target the mitochondria of cancerous cells based on their differences from normal
cells, the cancerous cells will be forced to undergo apoptosis.

1.4 Pancratistatin
While modification of known drugs continues to be an important aspect of
research, a vast amount of synthetic studies have
improvements in cancer research.

contributed

little to

Instead, current research is focusing on

finding new types of anti-cancer drugs that can more specifically target
cancerous cells (Taraphdar et al. 2001).
Epidemiological studies have shown a correlation between a reduced risk
of developing cancer and the consumption of relatively high amounts of major
sources of phyto-chemicals and micronutrients such as fruits and vegetables
(Reddy et al. 1997). This has lead scientists to look at natural sources such as
plants in order to uncover new anti-cancer agents.
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Paclitaxel (Taxol) is a natural compound isolated from the Pacific yew tree
that is currently in use as an anti-cancer therapy.

Although there are a large

number of side, effects associated with Paclitaxel treatment, this natural drug has
been shown to induce apoptosis in cancerous cells (Yeung et al. 1999).
As natural products are significantly contributing to the library of possible
anti-cancer compounds (Taraphdar et al. 2001), researchers are constantly on
the

look-out

for

novel

natural

compounds

with

anti-cancer

potential.

Pancratistatin or PST is one of these compounds that was isolated from the
spider lily Pancratium littorale in 1992 and has been found to exhibit anti
neoplastic activity (figure 1-4) (Luduena et al. 1992).

Previous work in our lab

has shown that PST can induce apoptosis in cancer cells at relatively low
concentrations (Kekre et al. 2005, Pandey et al. 2005).

However, the

biochemical mechanism by which PST induces apoptosis and the specificity of
PST for inducing apoptosis only in cancer cells is unknown.
Because of the low availability of naturally extracted PST and the difficulty
in the synthetic manufacturing of the drug, little advances have been made in the
clinical applications of PST.

A better understanding of how PST specifically

targets cancer cells will aid in the synthetic development of an active derivative
and give us a better understanding of how we can specifically target cancerous
cells.
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Figure 1-4: Structure of Pancratistatin

OH
,O H

HO

o

"O H
'H
NH

O'
OH

O

Figure 1-4:5 Structure of Pancratistatin
Pancratistatin (Ci4H15N 0 8) has a molecular weight of 325.28g/mol. The molecular structure is
show here.
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1.5 Objectives

In the present study, the objectives were to investigate if the natural
product Pancratistatin can effectively and selectively induce apoptosis in
cancerous cells. In order to accomplish this, we will be investigating the ability of
Pancratistatin to induce apoptosis in vitro using various cancerous cell lines
including neuroblastoma, mammary gland adenocarcinoma, mammary gland
carcinoma, and colorectal adenocarcinoma. In addition, we will be evaluating
whether this effect is specific to cancerous cells using several non-malignant cell
lines.
We will also explore the possible biochemical mechanism of action of
Pancratistatin-induced apoptosis in cancerous cells. Through this research, we
will evaluate the effect of PST treatment on various key players in the apoptotic
pathways in order to determine the activated apoptotic mechanism and
determine the biochemical target of PST.
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CHAPTER 2: MATERIALS
2.1 Cell culture
2.1.1 Cell lines
Human neuroblastoma (SHSY-5Y) cells (CRL-2266) were purchased from
the American Type Culture Collection (ATCC), Manassas, VA, USA. Normal
human fibroblast (NHF) cells (AG09309) were obtained from Coriell Institute for
Medical Research, Camden, NJ, USA. Mammary gland adenocarcinoma (MCF7) cells were obtained as a gift from Dr. Hubberstey and Dr. Porter, University of
Windsor. Human mammary epithelial (HMEC) cells were obtained from Martha
Stampfer, UC Berekely. Mammary gland carcinoma (Hs-578T) cells (HTB-126);
normal mammary gland fibroblast (Hs 578Bst) cells (HTB-125); colorectal
adenocarcinoma (HT-29) cells (HTB-38); and normal colon fibroblasts (CCD18Co) cells (CRL-1459) were obtained from the American Type Culture
Collection (ATCC), Manassas, VA, USA.

2.1.2. Media and supplements
Dulbecco’s modified Eagle’s medium (DMEM) / nutrient mixture Ham’s F12 medium; Earle’s minimum essential medium (EMEM); modified Dulbecco's
medium (MDM); minimum essential medium (Eagle) with 2 mM L-glutamine and
Earle's BSS (MEME); and McCoy's 5a medium were all obtained from Sigma
Chemical Company, Mississauga, Ontario, Canada.

Clonetic’s mammary

epithelial cell medium (MEGM) BulletKit (including Bovine Pituitary Extract (BPE),
Epidermal

Growth

Factor (EGF),

Hydrocortisone,

Ethanolamine,
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and

O-

Phosphothanolamine)

were

obtained

from

Cambrex

Corporation,

East

Rutherford, NJ, USA.
L-Glutarpine, Gentamycin, MEM Amino Acids Solution 5mM (50X), MEM
Non-Essential Amino Acids Solution 10mM (100X), and MEM Vitamin Solution
(100X) were purchased from Invitrogen Canada Inc., Burlington, Ontario,
Canada. Fetal bovine serum (FBS), Isoproterenol (+lsoproterenol: hydrochloride
crystalline), human transferrin, glucose, bovine insulin, epidermal growth factor
(EGF), sodium bicarbonate and sodium pyruvate were purchased from Sigma
Chemical Company, Mississauga, Ontario, Canada.

2.2 Pancratistatin and other anti-cancer drugs
Pancratistatin (PST) was obtained from our collaborator, Dr. James McNulty,
McMaster University, Hamilton, Ontario, Canada. PST was isolated from the bulb of
the Hymenocallis littoralis, a spider lily native to the islands of Hawaii, following a
previously published method (Pettit 1993). Etoposide (VP-16) and Paclitaxel (Taxol)
were both bought from Sigma Chemical Company, Mississauga, Ontario, Canada.

2.3 Other chemicals
Most of the additional chemicals including ATP, CHAPS, DTT, EDTA,
EGTA,

(D)-t-Glucose,

HEPES,

horse

radish

peroxidase

(HRP),

lucifrein-

luciferase, low melting point agarose, MgCI2, Na2EDTA, paraformaldehyde,
parahydroxyphenylacetic acid (PHPA), standard protein solution (bovine serum
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albumin),

succinate,

and trypsin

were

purchased from

Sigma Chemical

Company, Mississauga, Ontario, Canada.
Triton X-100 was obtained from Gibco BRL, VWR, Mississauga, Ontario,
Canada.

DMSO, KCI, KH2P 04, NaHP04, NaOH, NaCI, NaHC03 and sucrose

were purchased from BDH Inc., Toronto, ON, Canada.
NaCI and Tris were obtained from ACP, Montreal, Quebec, Canada. CaCI2
and agarose were purchased from EM Sciences, NJ, USA.
dichlorofluorescein

diacetate

(DCFDA),

5,5'

2', 7' -

^^'-tetrachloro-I.V .S.S1-

tetraethylbenzimidazolylcarbocyanine iodide (JC-1), Alexa Fluor 488
FITC Annexin-V binding assay kit, benzyloxycarbonyl- Asp-Glu-Val-Asp-7amido-4-methylcoumarin (z-DEVD-AMC), Hoechst-33342; Succinyl-Leu-Leu-ValTyr-7-amido-4-methylcoumarin (Suc-LLVY-AMC), APO-BrdU Tunnel Assay kit,
and Mitotracker Red CM-XH2-Ros dye were obtained from Molecular Probes of
Invitrogen Canada Inc., Burlington, Ontario, Canada.
Dual Sensor MitoCasp Assay Kit was purchased from Cell Technology
Inc., Mountain View, CA, USA.

Trypan blue stain was purchased from Life

Technologies, Mississauga, Ontario, Canada.

Bio-Rad Protein assay reagent

was purchased from Bio-Rad, Hercules, CA, USA. DEVD-fmk was obtained from
Calbiochem, Mississauga, Ontario, Canada.
Water-soluble Coenzyme Q i0 (CoQ10) was formulated at the National
Research Council (NRC), Ottawa, Canada, by a patented protocol developed by
Dr. Marianna Sikorska and Dr. Henryk Borowy-Borowsky (US patent # 6,045,
826).
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2.4 Apparatus and instrumentation
The Leica DM IRB fluorescent microscope was obtained from Leica,
Wetziar Germany. The multi-well plate reader, Spectra Max Gemini XS, was
obtained from Molecular Devices, Sunnyvale, California and the UV-Visible
Spectrophotometer was purchased from Agilent Technologies, Mississauga,
Ontario, Canada.
Cell culture was conducted under sterile conditions in a class-ll type A/B3
Biosafety cabinet (NuAire Inc., Plymouth, MN, USA), and all cultures were
maintained in a C 0 2 incubator containing a HEPA filter (Thermo Forma Scientific,
Inc, Marietta, OH, USA)
Centrifugation was conducted using a low speed Jouan CR3-I centrifuge
(Jouan by Thermo Electron Corporation, Waltham, MA, USA) and a MC2
DESAGA centrifuge

(Sarstedt-Gruppe,

Montreal,

laboratory equipment included the following:

Quebec).

Other general

a pH Meter (VWR, Model 8100)

with buffer solutions from VWR, Adventurer balance (OHAUS, Ontario, Canada),
Vortex Jr. Mixer from Scientific Industries Inc, 1296-002 DELFIA plate shaker
from Wallac, Rocking platform model 200 from VWR, and Corning stirrer from
Fisher Scientific.

Additionally, a Dounce homogenizer from Kontes Glass

Company (NJ, USA), freezer vials (VWR), and Eppendorf pipettes (Fisher
Scientific) were used.
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CHAPTER 3: METHODS
3.1 Cell Culture
3.1.1 In vitro Propagation of Cell Lines
SHSY-5Y and MCF-7 cells were grown at 37°C and 5% C 0 2 in DMEM /
Nutrient Mixture Ham’s F-12 medium modified to contain 2mM L-glutamine,
1.5g/L sodium bicarbonate, and 10mg/ml_ Gentamycin (90%) supplemented with
10% fetal bovine serum (FBS).
NHF cells were grown at 37°C and 5% C 0 2 in EMEM modified to contain
2mM

L-glutamine,

1.5g/L

sodium

bicarbonate

and

10mg/L

Gentamycin

supplemented with 15% FBS, 1X essential and 1X non-essential amino acids,
and 1X vitamins.
HME cells were grown at 37°C and 5% C 0 2 in MEGM with 70(ig/mL
Bovine Pituitary Extract (BPE), 5ng/mL Epidermal Growth Factor (EGF),
0.5pg/mL

Hydrocortisone,

10'4M

Ethanolamine,

and

10'4M

O-

Phosphothanolamine supplemented with 10'5M Isoproterenol and 5|ig/mLHuman
Transferrin.
Hs-578T cells were grown at 37°C and 5% C 0 2 in DMEM with 4 mM Lglutamine adjusted to contain 1.5g/L sodium bicarbonate, 10mg/L Gentamycin,
and 4.5g/L glucose supplemented with 0.01mg/mL bovine insulin and 10% fetal
bovine serum. Hs 578Bst cells were grown at 37°C and 5% C 0 2 in MDM with
30ng/mL EGF, 10mg/L Gentamycin, and 10% FBS.
HT-29 cells were grown at 37°C and 5% C 0 2 in modified McCoy's 5a
medium with 1.5mM L-glutamine adjusted to contain 2.2 g/L sodium bicarbonate
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and 10% FBS. CCD-18Co cells were grown at 37°C and 5% CO2 in MEME with
2mM

L-glutamine

and

Earle's

BSS adjusted to

contain

1.5g/L sodium

bicarbonate, 0.1 mM non-essential amino acids, 1.0mM sodium pyruvate and
»
10% FBS.

3.1.2 Sub-culturing of cells
Cells were sub-cultured by removing the culture medium by aspiration and
rinsing the cells with a 0.25% (w/v) trypsin - 0.53mM EDTA solution or Puck’s
solution (140mM NaCI, 5mM KCI, 5.5mM glucose, 4mM NaHC0 3 , 0.8mM
ethylenediamine tetraacetic acid or EDTA) in order to remove all traces of serum
(serum contains a trypsin inhibitor).

Additional 0.25% (w/v) trypsin - 0.53mM

EDTA solution was added and the cells were incubated at 37°C until the cell
layer began to disperse (usually within 1 to 10 minutes). Additional appropriate
complete media was added, cells were aspirated, and appropriate aliquots of the
cell suspension were added to new culture flasks or plates.

3.1.3 Transfection of SHSY-5Y cells
SHSY-5Y cells transfected with sdAB against the pro-apoptotic protein
BAX were obtained from Deyzi Georguieva and were produced by the
mammalian transfection of V hH fusion constructs (unpublished method). Briefly,
the transfection was initiated by inserting the VhH genes in the Hind lll/BamH I
sites

of

pEGFP-N1

(VHH-green

fluorescent

Biosciences, Mississauga, ON, Canada).

protein

(GFP)

fusion)

(BD

The VhH recombinant vectors were
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propagated in E. coli and were purified using a QIAprep® Spin Miniprep kit
according to the manufacturer’s instructions (QIAGEN, Mississauga, ON,
Canada). The purified plasmids were subsequently used to transfect SHSY-5Y
cells

using

Fugene

6 Transfection

Reagent

(Hoffmann-La

Mississauga, ON, Canada) following the manufacturer protocol.

Roche

Ltd.,

Forty eight

hours after transfection, cells were transferred to complete DMEM media (as
described above) containing 300 pg/ml Gentacin for selection of positive
transfected cells for 1-2 weeks. Stable cell lines were subsequently maintained
in complete DMEM media as described above with 200 pg/ml Gentacin.

3.2 Treatment of cells with anti-cancer drugs: PST, Taxol, and VP-16
Cells were grown to

70% confluence and treated with the

indicated

concentration of Pancratistatin (PST) by adding of PST directly to fresh complete
medium (1pM, unless other wise stated) for varying time periods. In order to compare
PST to other anti-cancer drugs currently in use, cells were also treated with 10pM VP16 and 500nM Taxol.

3.3 Data collection and analysis
All fluorescent and phase contrast pictures were taken using Improvision’s
OpenLab 3.1.5 Software on a Leica DM IRB fluorescent microscope. All pictures
were processed using Adobe Photoshop software. Fluorescence measurements
were collected using SoftMax PRO 3.1.2 software and a SpectraMax Gemini XS
fluorescent plate

reader.

Microsoft Excel software was used for data
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representation and statistical analysis. Statistical significance values were
obtained using analysis of variance (ANOVA) with a 95% confidence level using
StatSoft Statistica.
I

3.4 Assessment of apoptotic index
3.4.1 Nuclear and cellular microscopy
In order to examine morphological changes induced by PST treatment,
cancerous and non-cancerous cells were grown and treated with PST or other
anti-cancer drugs, followed by staining with 10pM of Hoechst-33342. The
fluorescent dye was directly added to the culture media and incubated for 10
minutes.

Cells were examined under a fluorescent microscope with phase

contrast and fluorescence pictures were taken.

3.4.2 Annexin-V binding assay
The cells were grown and treated as previously described. After various
treatment times, an annexin-V binding assay was conducted using a purchased
kit and the manufacturer’s protocol.

Cells were harvested via trypsinization,

washed twice using phosphate buffer saline (PBS) (0.137mM NaCI, 2.7mM KCI,
S.OmM Na2HP0 4 , 1.47mM KH2PO4) and then re-suspended in annexin-V binding
buffer (10mM HEPES and NaOH pH 7.5, 140mM NaCI, 2.5mM CaCI2) at a
concentration of -1 0 6 cells/mL.

100pL of each solution (-10 5 cells) was

transferred to eppendorf tubes, 5pL of annexin-V-FITC conjugate was added,
and the mixture was incubated for 15 minutes at room temperature.
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After

incubation, the cells were re-suspended in 100pL fresh binding buffer, and half of
the cells were stained with Hoechst 33342. Of the cells stained with Hoechst,
10pL of each suspension was transferred to a glass slide and covered with a
cover-slip. Slides were examined under a fluorescent microscope and pictures
were taken. Additionally, the other 100pL samples were diluted to 200pL with
binding buffer and the fluorescence was measured at excitation 499nm and
emission 519nm.

3.5 Assessment of DNA damage and degradation
3.5.1 Comet assay
A comet assay was performed on PST-treated SHSY-5Y and NHF cells
using a slight modification of a previously published method (Naderi et al. 2003).
Glass slides were pre-coated with 200pl of 0.1% agarose in such a way that half
of the gel was on the coarse surface and the other half on the smooth,
transparent surface. This was done because agarose gel tends to slide away
from the smooth surface during processing.

Treated and control cells were

harvested by trypsinization and 10pL of cell suspension (approximately 10,000
cells) was mixed with 80pL of warm 0.75% low-melting point agarose at 37°C.
The mixture was spread on a pre-coated glass slides. The slides were incubated
at 4°C for 5-10 minutes, until agarose was set. Slides were immediately
immersed in a tray containing freshly prepared cold lysis buffer (2.5M NaCI,
100mM Na2EDTA, 10mM tris at pH 10, 1% triton x-100 and 10% DMSO) and
incubated in the dark for 1 hour at 4°C. Following incubation, slides were washed
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in freshly prepared alkaline electrophoresis buffer (0.3M NaOH and 1mM
Na2EDTA at pH>13). The DNA was electrophoresed for 45 minutes at 300mA
(0.8V/cm), washed twice in a neutralizing buffer (0.4M tris, pH 7.5), and stained
with 10pM Hoechst 33342 in neutralizing buffer for 10 minutes. The cells were
examined under a fluorescent microscope and fluorescence pictures were taken.

3.5.2 Tunnel assay
In order to observe DNA fragmentation, an APO-BrdU Tunnel Assay was
preformed using the manufacturer’s protocol. Cells were grown and treated as
previously described. -1x106 cells were washed with PBS and incubated in 5mL
of 1% (w/v) paraformaldehyde in PBS on ice for 15 minutes.

The cells were

washed twice with PBS and re-suspended in 0.5mL of PBS. Cells were added to
5mL of ice-cold 70% (v/v) ethanol and set at -20°C overnight (at least 12 hours).
The next day, ethanol was removed by centrifugation and washed twice
using the wash buffer, provided in the kit. 50pl_ of DNA labeling solution was
prepared for each sample (10|uL of reaction buffer, 0.75pl_ of TdT enzyme, 8.0fj,L
of BrdUTP and 31.25pL of dH20 ) and cells were incubated for 60minutes in DNA
labeling solution at 37°C in a temperature controlled bath (shaken every 15
minutes). At the end of the incubation time, 1 .OmL of Rinse Buffer (provided in
the kit) was added to each tube followed by centrifugation.

The cells were

washed twice with Rinse Buffer and incubated in 100pL of antibody staining
solution (5pL Alexa Fluor 488 dye labeled anti-BrdU antibody, 95pL Rinse Buffer)
for 30minutes at room temperature. The samples were analyzed by fluorescence
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microscopy and the fluorescence was measured at excitation 495nm, emission
515nm.

3.6 Total and cytosolic cell lysate
Cells were harvested by mechanical dislodging using a rubber policeman
and centrifuged at 500xg for 5 minutes. The supernatant was removed and the
pellet was washed twice with 1X PBS pH 7.4 and centrifuged again at 500xg for
5 minutes. The supernatant was removed and the pellet was re-suspended in 0.4
ml of extraction buffer (25mM HEPES pH 7.25, 5mM MgCI2, 1mM EGTA, 0.1%
Triton X 100). The cell suspension buffer was transferred into a Dounce cell
homogenizer. Cells were homogenized with -2 0 strokes to produce the total cell
lysate.

Cytosolic cell lysates were obtained by an additional centrifugation at

800xg. The supernatant was collected as the cytosolic cell lysate.

3.7 Protein estimation
The concentration of proteins present in the total or cytosolic cell lysate
samples was estimated using a protocol from BioRad Laboratories. Protein
estimation was conducted by adding 10pL aliquots of each cell lysate sample,
790 pL of water and 200pl of BioRad protein assay reagent into 1mL plastic
cuvettes. The mixtures were vortexed and allowed to stand for 10 minutes at
room

temperature.

The

absorbance

was

then

measured

a

UV-Visible

Spectrophotometer and analyzed at 595 nm. A standard curve was prepared by
using various amounts of a standard protein solution (bovine serum albumin).
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3.8 Assays for the activation of proteases

3.8.1 Caspase-3 and proteasome activation
I

Proteasome and caspase-3 assays were performed using a previously
published method (Naderi et at. 2003). Cytosolic cell lysates from various cells
lines were used for the protease assays based on a fluorogenic substrate, which
is a tetra peptide sequence corresponding to the substrate cleavage site. LLVYAFC was used to detect proteasome activity in LLVYase buffer (1mM tris and
0.5mM MgCI2) and DEVD-AFC was used to detect caspase-3 activity in
DEVDase buffer (10mM HEPES, 2mM DTT, 0.01% CHAPS and 1% Sucrose)
according to the manufacturer’s protocol. The fluorescence was measured at
excitation 400nm, emission 505nm for caspase-3 and excitation 370nm,
emission 440nm for proteasome in a 96 well micro-titer plate using the Spectra
Max Gemini XS. Protein concentration was measured as previously described
and the caspase-3 and proteasome activities were calculated per microgram of
protein.

3.8.2 Caspase-3 inhibition assay
In addition, a caspase-3 inhibition assay was preformed. MCF-7 and Hs578T cells were pre-treated with the caspase-3 inhibitor molecule DEVD-fmk
according to the manufacturer’s instructions.

Caspase-3 inhibitor was directly

added to the culture media to a final concentration oflOpM. After 30 minutes,
cells were treated with 1pM of PST. Following treatment, cells were stained with
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10|j M Hoechst 33342 as described and the cells were examined under a
fluorescent microscope.

3.9 Trypan blue staining:
The Trypan blue exclusion test is a common method to measure the
number of viable cells in a given sample. Cells were trypsinized as previously
described, except that floating cells were spun down and added to the cell
suspension.

Fresh media was added and 20pL of the cell suspension was

added to 10pl_ of 0.4% Trypan blue stain.

Cells were counted using a

hemacytometer and the number of cells per volume unit of sample was
calculated.

3.10 Long-term drug resistance and viability study:
An eight day study of treated NHF and MCF-7 cells allowed for observing
any long-term effects of PST treatment on the growth of normal cells and if
cancerous cells can develop drug resistance. NHF and MCF-7 cells were grown
and treated as previously described.

After 48 hours of treatment, cells were

washed with fresh complete media and any floating cells were centrifuged and
added back into the plates. Morphological pictures were taken, and cells were
incubated for an additional 48 hours. Again, morphological pictures were taken.
Cells were then trypsinized and plated on fresh plates (2:1 split). The number of
viable cells was evaluated by taking 20pL of cell suspension and staining with
trypan blue before plating as previously described. The cells were then allowed
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to grow for 48 hours.

Again, morphological pictures were taken, cells were

harvested by typsinization and counted before plating.

After an additional 48

hour incubatior\ period under normal growth conditions, cells were harvested and
counted a third time.

3.11 Total reactive oxygen species generation:
Cells were treated with PST and production of total reactive oxygen
species (ROS) was measured with the membrane permeable dye 2', 7' dichlorofluorescein diacetate (DCFDA) using a slight modification of a previously
published procedure (Siraki et al. 2002). Cells were mechanically harvested
using a rubber policeman and washed with PBS. Cells were incubated in 10pM
DCFDA at 37°C for 20 minutes and fluorescence was measured at excitation
500nm, emission 520nm using a Spectra Max Gemini XS multi-well plate
fluorescence

reader.

Protein

concentration

was

measured

as

previously

described and results were calculated per microgram of protein.

3.12 Mitochondrial membrane permeability
3.12.1 JC-1 staining
Mitochondrial membrane permeability was visualized using 5,5' ,6,6'tetrachloro-1,1' ,3,3' -tetraethylbenzimidazolylcarbocyanine iodide (JC-1) dye
according to the manufacturer’s protocol and a previously published method
(Olichon et al. 2003). The cells were grown and treated as previously described.
The cells were incubated in media containing 0.5 -5pM of JC-1 dye for 15
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minutes and the media was replaced by PBS (floating cells were re-added after
centrifugation). The cells were examined under a fluorescent microscope and
pictures were taken.

3.12.2 Mitotracker red staining
Additionally,

mitochondrial

membrane potential was detected

using

Mitotracker CM-XH2-Ros dye (mitotracker red) according to the manufacturer’s
instructions. The cells were incubated in media containing 0.5pM of mitotracker
red dye for 15 minutes. The media containing the dye was removed and replaced
by PBS. The cells were examined under a fluorescent microscope and
fluorescence pictures were taken.

3.12.3 Mito-casp
To measure the both the loss in mitochondrial membrane potential and the
activation of caspases simultaneously, the Dual Sensor MitoCasp Assay Kit was
used according to the manufacturer’s protocol. Cells were grown and treated as
previously described. Cells were removed by trypsinization, washed twice with
PBS, and re-suspended in 0.5ml_ of PBS.

100pL samples of suspended cells

were incubated in the cationic mitochondrial membrane potential dye (MMP dye)
reagent and FAM-VAD-FMK caspase detection reagent for 60minutes at 37°C.
After the incubation period, the cells were washed twice in wash buffer and the
fluorescence was measured at 488nm excitation, 530nm emission (for caspase
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detection) and at 549nm excitation, 574nm emission (mitochondria membrane
potential loss). The results were calculated as fluorescence per 10,000 cells.
»
3.13 Assay for ATP concentration
Cells were grown and treated as previously described and an assay for
ATP concentration was completed according to a previously published method
(McCarthy et al. 2004). In order to measure ATP levels, 100pL of cytoplasmic
cell

suspension

was

incubated

with

5mg/mL

luciferin-luciferase

and

bioluminescence was measured at 560nm using the Spectra Max Gemini XS.
Total cell ATP levels were determined using an assay of internal standards.
Protein was estimated as previously described and the results were calculated
per microgram of protein.

3.14 Assessment of ROS generation in isolated mitochondria
3.14.1 Mitochondrial isolation
Intact mitochondria were isolated from cells using a previously published
method (Li et al. 2003). Cells were collected by centrifugation at 500xg for 5
minutes. The pellet was washed twice with ice cold PBS and centrifuged at
250xg. The pellet was re-suspended in isolation buffer containing 1mM EDTA,
10mM HEPES (pH 7.4) and 250mM sucrose. Cells were homogenized and the
disrupted cells were centrifuged for 5 minutes at 600xg at 4°C. The supernatant
was collected and centrifuged at 15 OOOxg at 4°C for 5 minutes and the resulting
pellet was considered to be crude mitochondria. The pellet was re-suspended in
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isolation buffer without EDTA. Mitochondrial suspensions were kept on ice and
all of the experiments were performed within 2 hours of centrifugation.

4.14.2 Treatment of isolated mitochondria
Isolated

mitochondria from

control cells were

subjected to direct

incubation with 1pM PST for various times or were pre-treated for 15 minutes
with 30pig/mL water-soluble Coenzyme Q i0 (CoQ10).

4.14.3 Mitochondrial ROS generation
Mitochondrial

ROS

generation

was

measured

using

Parahydroxyphenylacetic acid (PHPA) and approximated by an increase in the
fluorescence

due

to

oxidized

p-hydroxyphenylacetate

fluorescence

by

horseradish peroxidase (HRP), based on a previously published protocol (Li etal.
2003). In a 96 well micro-titer plate, 0.25 mg of mitochondrial suspension was
added to a 100pl reaction mixture containing 0.25M sucrose, 1mM MgCI2, 10mM
HEPES, 0.5mg/mL PHPA and 0.4 units of HRP per well. Lastly, 100mM
succinate was added and the contents were mixed. After a 30 minute incubation
period, the fluorescence of oxidized PHPA was measured in a 96 well micro-titer
plate at excitation 320nm and emission 400nm using the Spectra Max Gemini
XS. Total mitochondrial protein was estimated using the BioRad method and the
results were calculated per microgram of protein.
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CHAPTER 4: RESULTS
4.1 Induction of apoptosis in cancer cells treated by Pancratistatin
Previous, work in our laboratory has shown that 1|iM of PST is effective in
inducing apoptosis in rat hepatoma (5123) and other cells (Pandey et al. 2005).
Here we further evaluated the effectiveness of PST to induce apoptosis in
several types of cancerous cells. SHSY-5Y (neuroblastoma), MCF-7 (mammary
gland adenocarcinoma), Hs578-T (mammary gland carcinoma), and HT-29
(colorectal adenocarcinoma) cells were treated with PST for various time periods
as previously described and various morphological and biochemical changes
were observed.

4.1.1 The minimum effective Pancratistatin concentration
Nuclear condensation and membrane blebbing are hallmark features of
apoptosis.

In order to observe the nuclear morphological changes induced by

PST in cancer cells, the treated cells were stained with Hoechst-33342 dye.
In order to calculate the ideal concentration for PST treatment, MCF-7
(mammary gland adenocarcinoma) cells were treated with 250nm, 500nm, 1pM,
2pM, and 4pM of PST for 48 hours, as described. Nuclear morphology pictures
were taken in order to observe changes characteristic of apoptosis such as DNA
condensation, cell shrinkage, and the formation of apoptotic bodies. In addition,
the number of cells displaying these features was counted. Figure 4-1 a and b
reveal that PST treatment induces an increase in the number of cells displaying
apoptotic features.

The number of apoptotic nuclei only increases slightly at
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concentrations higher than 1pM, and therefore 1|iM was chosen as the minimum
effective dose. Analogous assays were preformed with the other cancerous cell
lines and the results were found to be similar (data not shown).

4.1.2 Sensitivity of cancerous cells to Pancratistatin treatment
In addition, the sensitivities of the cancerous cell lines to 1pM PST were
evaluated at various treatment times.

SHSY-5Y, MCF-7, Hs578-T, and HT-29

cells were treated with 1pM PST for 3, 6, 12, 24, 48, 72, and 96 hours and the
cells were stained with Hoechst-33342 dye, as described.
Figure 4-2a and b indicate that there is an increase in the number of
apoptotic SHSY-5Y cells after only 3 hours of PST treatment (10%), as indicated
by an increase in the number of cells exhibiting nuclear condensation. More than
90% of the treated SHSY-5Y cells appear to have nuclear condensation after 24
hours. Further stages of apoptosis are made evident by membrane blebbing and
cell detachment from the plates after 48 hours of treatment.
Similarly, figure 4-3a and b indicate that there is an increase in the
number of apoptotic MCF-7 cells after approximately 48 hours of PST treatment
(55%) as suggested by an increase in the number of cells exhibiting nuclear
condensation. More than 95% of the treated cells appear to be apoptotic after 96
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Figure 4-1 a: Dose response of MCF-7 cells to Pancratistatin
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Figure 4-1 a: Dose response of MCF-7 cells to Pancratistatin
MCF-7 cells were treated with PST and stained with Hoechst 33342 dye to examine nuclear
morphology. Fluorescent pictures were taken after 48 hours of treatment at 400x magnification.
Nuclear condensation is evident in cells with bright, condensed, and rounded nuclei.

Figure 4-1 b: Apoptotic Index: Dose response of
MCF-7 cells to Pancratistatin
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Figure 4-1 b: Apoptotic Index: Dose response of MCF-7 cells to Pancratistatin
MCF-7 cells were treated with PST for 48 hours and stained with Hoechst 33342 dye. The
number of apoptotic nuclei was counted and the average percentage of apoptotic cells was
calculated from a minimum of 500 cells. Standard errors were calculated using data from a
minimum of three separate sets of experiments.
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Figure 4-2a: Pancratistatin induces apoptosis in
SHSY-5Y cells
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Figure 4-2a: Pancratistatin induces apoptosis in SHSY-5Y cells
SHSY-5Y cells were treated with 1pM of PST and stained with Hoechst 33342 dye to examine
nuclear morphology. Fluorescent pictures were taken at 400x magnification. Nuclear
condensation is evident in cells with bright, condensed, and rounded nuclei.

Figure 4-2b: Apoptotic index of SHSY-5Y cells treated
with Pancratistatin
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Figure 4-2b: Apoptotic index of SHSY-5Y cells treated with Pancratistatin
SHSY-5Y cells were treated with 1pM PST and stained with Hoechst 33342 dye. The number of
apoptotic nuclei was counted and the average percentage of apoptotic cells was calculated from
a minimum of 500 cells. Standard errors were calculated using data from a minimum of three
separate sets of experiments.
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Figure 4-3a: Pancratistatin induces apoptosis in MCF-7 cells
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Pancratistatin induces apoptosis in MCF-7 cells

MCF-7 cells were treated with 1pM of PST and stained with Hoechst 33342 dye to examine
nuclear morphology. Fluorescent pictures were taken at 400x magnification. Nuclear
condensation is evident in cells with bright, condensed, and rounded nuclei.

Figure 4-3b: Apoptotic index of MCF-7 cells treated
with Pancratistatin
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Apoptotic index of MCF-7 cells treated with Pancratistatin

MCF-7 cells were treated with 1pM of PST and stained with Hoechst 33342 dye. The number of
apoptotic nuclei was counted and the average percentage of apoptotic cells was calculated from
a minimum of 500 cells. Standard errors were calculated using data from three separate sets of
experiments.
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hours as indicated by nuclear condensation and detachment of cells from the
plates.
Hs578-T and HT-29 cells treated with PST exhibit similar results. Figure
4-4a and b indicate that after 72 hours a large number of Hs578-T cells exhibit
nuclear condensation (over 90%) and, after 96 hours, membrane blebbing is
evident and many of the cells are detached from the plates. Figure 4-5a and b
depict that after 96 hours of PST treatment over 90% of cells are apoptotic as
established by nuclear condensation and membrane blebbing.

4.1.3 Annexin-V binding
Annexin-V binding measures another characteristic feature of apoptosis:
phosphatidyl serine flipping across the plasma membrane. This assay was used
to confirm that the cancerous cells treated with PST were indeed undergoing
apoptosis. After induction of apoptosis, cells were stained with Annexin-V and
examined under a fluorescent microscope.
SHSY-5Y cells treated with PST showed a dramatic increase in Annexin-V
staining after 24 hours of treatment (figure 4-6a and b), while MCF-7 cells
showed increase after 48 hours (figure 4-7a and b). ANOVA indicated that the
SHSY-5Y control and 24 hour values were significantly different (p = 0.001385)
and that the MCF-7 control and 96 hour values were also significantly different (p
=0.010938). These results confirm that PST induces apoptosis in both SHSY-5Y
and MCF-7 cells; however, different types of cancerous cells may require longer
treatment regiments.
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Figure 4-4a: Pancratistatin induces apoptosis in
HS578-T cells
I

Figure 4-4a:
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7 2 hrs PST

9 6 hrs PST

Pancratistatin induces apoptosis in Hs578-T cells

Hs578-T cells were treated with 1pM of PST and stained with Hoechst 33342 dye to examine
nuclear morphology. Fluorescent pictures were taken at 400x magnification. Nuclear
condensation is evident in cells with bright, condensed, and rounded nuclei.

Figure 4-4b: Apoptotic index of Hs578-T cells treated with
Pancratistatin

Control

Figure 4-4b:

12hrs

24hrs

48hrs

72hrs

96hrs

Apoptotic index of HT-29 cells treated with Pancratistatin

HT-29 cells were treated with 1pM of PST and stained with Hoechst 33342 dye. The number of
apoptotic nuclei was counted and the average percentage of apoptotic cells was calculated from
a minimum of 500 cells. Standard errors were calculated using data from three separate sets of
experiments.
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Figure 4-5a: Pancratistatin induces apoptosis in HT-29 ceils

Control

Figure 4-5a:

24 hrs

Pancratistatin induces apoptosis in HT-29 cells

HT-29 cells were treated with 1pM of PST and stained with Hoechst 33342 dye to examine
nuclear morphology. Fluorescent pictures were taken at 400x magnification. Nuclear
condensation is evident in cells with bright, condensed, and rounded nuclei.

Figure 4-5b: Apoptotic index of HT-29 cells treated with
Pancratistatin
100 1
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Figure 4-5b:

12hrs

24hrs

48hrs

72hrs

96hrs

Apoptotic index of Hs578-T cells treated with Pancratistatin

Hs578-T cells were treated with 1pM of PST and stained with Hoechst 33342 dye. The number of
apoptotic nuclei was counted and the average percentage of apoptotic cells was calculated from
a minimum of 500 cells. Standard errors were calculated using data from three separate sets of
experiments.
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Figure 4-6a: AnnexinV staining in SHSY-5Y cells treated with
Pancratistatin

24 hrs

Figure 4-6a:

12 hrs

6 hrs

C o n tro l

48 hrs

AnnexinV staining in SHSY-5Y cells treated with Pancratistatin

SHSY-5Y cells were treated with 1pM of PST and stained with AnnexinV to examine phosphatidyl
serine flipping across the plasma membrane. Fluorescent pictures were taken at 400x
magnification. Membrane flipping is evident in those cells displaying fluorescence.

Figure 4-6b: AnnexinV fluorescence in SHSY-5Y ceils treated
with Pancratistatin
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Figure 4-6b:
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12hrs

24hrs

48hrs

AnnexinV fluorescence in SHSY-5Y cells treated with Pancratistatin

SHSY-5Y cells were treated with 1p.M of PST and stained with AnnexinV, as described. The
fluorescence was measured and the average percentage of control fluorescence per 10 000 cells
and standard deviation were calculated using the data of three separate experiments.
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Figure 4-7a: AnnexinV staining in MCF-7 cells
treated with Pancratistatin
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Figure 4-7a:
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AnnexinV staining in MCF-7 cells treated with Pancratistatin

MCF-7 cells were treated with 1(xM of PST and stained with AnnexinV to examine phosphatidyl
serine flipping across the plasma membrane. Fluorescent pictures were taken at 400x
magnification. Membrane flipping is evident in those cells displaying fluorescence.

Figure 4-7b: AnnexinV fluorescence in MCF-7 cells
treated with Pancratistatin
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Figure 4-7b:

24hrs

48hrs

72hrs

96hrs

AnnexinV fluorescence in MCF-7 cells treated with Pancratistatin

MCF-7 cells were treated with 1pM of PST and stained with AnnexinV, as described. The
fluorescence was measured and the average percentage of control fluorescence per 10 000 cells
and standard deviation were calculated using the data of three separate experiments.
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4.1.4 DNA fragmentation in cancerous cells

DNA fragmentation is another key feature of apoptosis.

This was

examined in cejls treated with PST using the comet assay or the tunnel assay.
The comet assay was used to evaluate the extent of DNA fragmentation in
SHSY-5Y cells. As seen in figure 4-8, SHSY-5Y cells treated with PST do not
exhibit DNA damage during the early phases of treatment indicating that PST is
not causing DNA damage to induce apoptosis.

Even after 17 hours of PST

treatment, the amount of DNA damage is minimal, while the DNA damage
induced by VP16 and taxol is massive at 17 hours. The presence of a comet
after 24 hours in most SHSY-5Y cells indicates that DNA fragmentation is
occurring as a consequence of apoptosis.
MCF-7 and Hs578-T cells show similar results. The Tunnel assay revelled
that after 72 hours there is a significant increase in the amount of DNA
fragmentation in PST treated MCF-7 cells (figure 4-9a and b) and Hs578-T cells
(figure 4-1 Oa and b).
Here we have shown that nuclear condensation, membrane blebbing,
DNA fragmentation

and

phosphatidyl

serine flipping

across the

plasma

membrane all occur following Pancratistatin treatment in cancerous cells. Taken
together, these results support our hypothesis that PST effectively induces
apoptotic cell death in cancerous cells.

In order to evaluate the specificity of

Pancratistatin, we next investigated whether or not this apoptotic effect occurred
in normal cells treated with Pancratistatin.
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Figure 4-8: Comet assay of SHSY-5Y cells

Control

3 Hrs PST

17 hrs PST

17 hrs VP16

Figure 4-8:

Comet assay of SHSY-5Y cells

SHSY-5Y cells were treated with PST, Taxol, and VP-16 and a comet assay was completed as
described. Cells were stained with Hoechst 33342 dye and pictures were taken at 400x
magnification. DNA degradation is indicated by comet-like images due to migration of damaged
DNA during electrophoresis.
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Figure 4-9a: Tunnel assay of MCF-7 cells treated with
Pancratistatin

Figure 4-9a:
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Tunnel assay of MCF-7 cells treated with Pancratistatin

MCF-7 cells were treated with PST and a tunnel assay was completed as described and pictures
were taken at 400x magnification. DNA fragmentation is indicated by bright fluorescent staining.

Figure 4-9b: Tunnel assay fluorescence of MCF-7 cells
treated by Pancratistatin
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Figure 4-9b:

24hrs

48hrs

72hrs

96hrs

Tunnel assay fluorescence of MCF-7 cells treated by Pancratistatin

MCF-7 cells were treated with 1pM of PST and a tunnel assay was completed, as described. The
fluorescence was measured and the average fluorescence per 10 000 cells and standard
deviation were calculated using the data of three separate experiments.
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Figure 4-1 Oa: Tunnel assay of Hs578-T cells treated by
Pancratistatin

Control

Figure 4-1 Oa:

48hrs

Tunnel assay of Hs578-T cells treated by Pancratistatin

Hs578-T cells were treated with PST and a tunnel assay was completed as described and
pictures were taken at 400x magnification. DNA fragmentation is indicated by bright fluorescent
staining.

Figure 4-1 Ob: Tunnel assay fluorescence of Hs578-T cells
treated by Pancratistatin
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Figure 4-1 Ob:

24hrs

48hrs

72hrs

96hrs

Tunnel assay fluorescence of Hs578-T cells treated by Pancratistatin

Hs578-T cells were treated with 1pM of PST and a tunnel assay was completed, as described.
The fluorescence was measured and the average fluorescence per 10 000 cells and standard
deviation were calculated using the data of three separate experiments.
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4.2 Pancratistatin treatment does not induce apoptosis in normal cells

One of the main problems with current anti-cancer drugs is the lack of
specificity to capcer cells. Our results clearly indicated that PST is very effective
in inducing apoptosis in cancerous cells. However, in order to determine PST’s
potential as an anti-cancer agent, the effect of PST on normal, dividing, noncancerous cells must be evaluated.

Here, four different normal cell lines were

used to determine if PST has any negative affects on non-cancerous cells.
NHF (normal human fibroblasts), Hs578-Bst (normal mammary gland
fibroblasts), CCD-18Co (normal colon fibroblasts), and HMEC (human mammary
epithelial cells) were treated with PST and, after 3, 6, 24, 48, and 96 hours,
various morphological and biochemical changes were observed as described
below.

4.2.1 Nuclear morphology of non-cancerous cells
In order to observe if PST induced apoptosis in normal non-cancerous
cells, the nuclear morphology of the cells was observed using Hoechst-33342
dye and fluorescent pictures were taken.

Figures 4-11a depicts that PST

treatment induces no nuclear morphological changes in NHF cells, even after 96
hours of PST exposure. Figure 4-11b and c depicts cells that were treated with
PST, VP16, and Taxol. After 24 hours, cells treated with VP16 show signs of
apoptosis and those treated with Taxol exhibit extensive damage, including
nuclear condensation and membrane blebbing. Cells treated with PST show no
signs of damage and appear identical to the control cells.
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Figure 4-11a: Pancratistatin does not induce apoptosis in
NHF cells

Figure 4-11a:

Control

3 hrs

6 hrs

24 hrs

48 hrs

96 hrs

Pancratistatin does not induce apoptosis in NHF cells

NHF cells were treated with 1juM of PST and stained with Hoechst 33342 dye to examine nuclear
morphology. Fluorescent pictures were taken at 400x magnification. Nuclear condensation is
evident in cells with bright, condensed, and rounded nuclei.

Figure 4-11b: Apoptosis induced in NHF cells treated by PST,
Taxol, and VP16

Figure 4-11b:
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Apoptosis induced in NHF cells treated by PST, Taxol and VP16

NHF cells were treated with 1pM of PST, 10pM of VP16, and 500nm of Taxol and stained with
Hoechst 33342 dye to examine nuclear morphology. Fluorescent pictures were taken at 400x
magnification. Nuclear condensation is evident in cells with bright, condensed, and rounded
nuclei.
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Figure 4-11c: Apoptotic index of NHF cells treated by
Pancratistatin, Taxol, and VP16
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Apoptotic index of NHF cells treated by Pancratistatin, Taxol and VP16

NHF cells were treated with IpM of PST, 56
; 7r ' ‘ of VP16, and 500nm of Taxol and stained with
Hoechst 33342 dye. The number of apoptotic nuclei was counted and the average percentage of
apoptotic cells was calculated from a minimum of 500 cells. Standard errors were calculated
using data from three separate sets of experiments.
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Similarly, HMEC cells treated with PST are shown in figure 4-12a. There
are no visible nuclear changes in cells treated with PST for up to 96 hours.
Figure 4-12b and c indicate that HMEC cells treated with PST, VP16 and Taxol
are stained with Hoechst-33342 and only have an increase in the number of
apoptotic nuclei when the cells are treated with VP16 and Taxol. Figure 4-13a
and b show that Hs578-Bst cells treated with PST show no signs of apoptosis
even after 96 hours of treatment.

CCD-18Co cells treated with PST illustrate

similar results (figure 4-14a and b).

4.3.2 Annexin-V binding
NHF cells treated with PST were also subjected to an Annexin-V binding
assay to provide a secondary method for apoptosis detection. As indicated by
figure 4-15a and b, no increase in the amount of Annexin-V staining can be seen
or detected (p>0.05) even after 96 hours of PST treatment.

4.3.3 PST does not induce DNA fragmentation in normal cells
A comet assay was used to evaluate if PST induced DNA damage or
degradation in NHF cells. These effects were compared to those of the currently
used anti-cancer therapies: Taxol and VP16.

Figure 4-16 depicts substantial

DNA damage in the NHF cells treated with Taxol; while the cells treated with PST
and VP-16 appear similar to control.
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Figure 4-12a: Apoptosis in HMEC cells treated with PST,
VP16, and Taxol
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Apoptosis in HMEC cells treated with PST, VP16, and Taxol

HMEC cells were treated with 1(j.M of PST, 10pM of VP16, and 500nm of Taxol and stained with
Hoechst 33342 dye to examine nuclear morphology. Fluorescent pictures were taken at 400x
magnification. Nuclear condensation is evident in cells with bright, condensed, and rounded
nuclei.

Figure 4-12b: Apoptotic Index of HMEC cells treated with
PST, VP16, and Taxol
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Apoptotic Index of HMEC cells treated with PST, VP16, and Taxol

HMEC cells were treated with 1pM of PST, 10pM of VP16, and 500nm of Taxol and stained with
Hoechst 33342 dye. The number of apoptotic nuclei was counted and the average percentage of
apoptotic cells was calculated from a minimum of 500 cells. Standard errors were calculated
using data from three separate sets of experiments.
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Figure 4-13a: Pancratistatin does not induce apoptosis in
Hs578-Bst cells

Control

Figure 4-13a:

48 hrs PST

96 hrs PST

Pancratistatin does not induce apoptosis in Hs578-Bst cells

Hs578-Bst cells were treated with 1 pM of PST and stained with Hoechst 33342 dye to examine
nuclear morphology. Fluorescent pictures were taken at 400x magnification. Nuclear
condensation is evident in cells with bright, condensed, and rounded nuclei.

Figure 4-13b: Apoptotic index of
Hs578-Bst cells treated by Pancratistatin
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Figure 4-13b:
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Apoptotic index of Hs578-Bst cells treated by Pancratistatin

Hs578-Bst cells were treated with 1 pM of PST and stained with Hoechst 33342 dye. The number
of apoptotic nuclei was counted and the average percentage of apoptotic cells was calculated
from a minimum of 500 cells. Standard errors w ere calculated using data from three separate
sets of experiments.
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Figure 4-14a: Pancratistatin does not induce apoptosis in
CCD-18Co cells

Control

Figure 4-14a:

72 hrs PST

Pancratistatin does not induce apoptosis in CCD-18Co cells

CCD-18Co cells were treated with 1pM of PST and stained with Hoechst 33342 dye to examine
nuclear morphology. Fluorescent pictures were taken at 400x magnification. Nuclear
condensation is evident in cells with bright, condensed, and rounded nuclei.

Figure 4-14b: Apoptotic index of CCD-18Co cells
treated by Pancratistatin
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Figure 4-14b:
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96hrs

Apoptotic index of CCD-18Co cells treated by Pancratistatin

CCD-18C cells were treated with 1pM of PST and stained with Hoechst 33342 dye. The number
of apoptotic nuclei was counted and the average percentage of apoptotic cells was calculated
from a minimum of 500 cells. Standard errors were calculated using data from three separate
sets of experiments.
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Figure 4-15a: AnnexinV binding in NHF cells treated
with Pancratistatin
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AnnexinV binding in NHF cells treated with Pancratistatin

NHF cells were treated with 1|iM of PST and stained with AnnexinV to examine phosphatidyl
serine flipping across the plasma membrane. Fluorescent pictures were taken at 400x
magnification. Membrane flipping is evident in those cells displaying fluorescence.

Figure 4-15b: AnnexinV fluorescence in NHF cells
treated with Pancratistatin

200.00
180.00
§

160.00

*5

140.00

vfl
0
s

120.00
100.00

80.00
60.00
40.00
20.00
0.00

Control

Figure 4-15b:
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AnnexinV fluorescence in NHF cells treated with Pancratistatin

MCF-7 cells were treated with 1pM of PST and stained with AnnexinV, as described. The
fluorescence was measured and the average percentage of control fluorescence per 10 000 cells
and standard deviation were calculated using the data of three separate experiments.
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Figure 4-16: Comet assay in NHF cells treated
with Pancratistatin

Figure 4-16:
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Comet assay of NHF cells treated with Pancratistatin

NHF cells were treated with PST, Taxol, and VP-16 and a comet assay was completed as
described. Cells were stained with Hoechst 33342 dye and pictures were taken at 400x
magnification. DNA degradation is indicated by comet-like images due to migration of damaged
DNA during electrophoresis.
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A tunnel assay was used as an alternate method for the comet assay.

In

figure 4-17a and b, HMEC cells treated with PST show tunnel staining similar to
the control and no significant change in the amount of fluorescence could be
detected (p>0.05).

4.3 Pancratistatin treatment does not affect the long term growth and
proliferation of normal cells
Although PST did not induce apoptosis in normal cells even after 96 hours
of treatment, a long-term growth and proliferation study of normal cells after PST
treatment was used in order to rule out the possibility that PST may cause other
toxicities that may affect the growth and function of normal cells. NHF cells were
treated with PST for 48 hours followed by incubation in fresh media. Cells were
then treated as regular stock cells (trypsinization, counting, and plating) for an
additional 6 days, as previously described.
Figure 4-18a shows pictures taken immediately following the 48 hour
treatment, 48 hours after fresh media was added, and 48 hours after cells were
split for the first time.

No morphological changes were detected using

microscopy techniques. In addition, the number of viable cells was counted at
each split (every 48 hours) using trypan blue staining. The average growth of
cells was calculated from two time points 48 hours apart and the PST treated
cells did not shown any differences from the control in the growth rate of cells
(figure 4-18b). An ANOVA indicated that the treated values were not significantly
different from control values at all time points (p>0.05).
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Figure 4-17a: Tunnel assay staining in HMEC cells treated
with Pancratistatin
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Tunnel assay staining in HMEC cells treated with Pancratistatin

HMEC cells were treated with PST and a tunnel assay was completed as described and pictures
were taken at 400x magnification. DNA fragmentation is indicated by bright fluorescent staining.

Figure 4-17b: Tunnel assay fluorescence in HMEC cells
treated with Pancratistatin
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Figure 4-17a:
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Tunnel assay fluorescence in HMEC cells treated with Pancratistatin

Hs578-T cells were treated with 1pM of PST and a tunnel assay was completed, as described.
The fluorescence was measured and the average fluorescence per 10 000 cells and standard
deviation were calculated using the data of three separate experiments.
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Figure 4-18a: Pancratistatin does not affect the growth of
NHF cells
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Figure 4-18a:

Pancratistatin does not affect the growth of NHF cells

NHF cells were treated with 1|iM of PST and after 48 hours of treatment, the treatment media
was replaced by fresh media. Phase contrast pictures were taken at 400x magnification 48 hours
after the end of treatment and 48 hours after each time the cells were split. Apoptosis is evident in
cells with cellular beading, membrane blebbing, and lifting from the surface.

Figure 4-18b: Growth curve of NHF cells treated
with Pancratistatin
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Figure 4-18b:

Growth Curve of NHF cells treated with Pancratistatin

NHF cells were treated for 48 hours with PST and then given fresh media. After 48 hours, cells
were split and trypan blue was used to measure the number of viable NHF cells, as described.
Cells were spilt and counted two additional times at 48 hour intervals. Results were calculated
using data from three separate sets of experiments.
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4.4 Once treated with Pancratistatin, MCF-7 cells to not recover and
eventually die by apoptosis
MCF-7 cells are notorious for developing drug resistance (Simstein et at.
2003). In order to investigate if MCF-7 cells can recover once treated by PST, a
long-term study of the growth and proliferation of MCF-7 cells treated with
Pancratistatin was conducted. MCF-7 cells were treated with PST for 48 hours
followed by incubation in fresh media without PST. As with the NHF cells, the
MCF-7 cells were treated as regular stock cells for an additional 6 days. The
number of viable cells at each split is depicted in figure 4-19. 96 hours after the
surviving cells were put into fresh media, no live cells could be detected using
trypan blue staining.
In this study, we have shown that Pancratistatin can selectively and
effectively induce apoptosis in cancerous cells, indicating that PST may be an
effective anti-cancer agent. Apoptosis was successfully induced in several types
of cancerous cells treated with a low-dose of Pancratistatin and a 48 hour
treatment is enough to induce apoptosis in MCF-7 cells even after the treatment
is removed. Interestingly, normal, non-cancerous cells were not affected by PST.
An investigation into the mechanism of PST induced apoptosis in cancerous cells
may allow us to determine why this differential effect is observed.
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Figure 4-19: 48 hours of PST exposure leads to 100%
apoptosis in MCF-7 cells even after the removal of the PST
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Figure 4-19:4148 hours of PST exposure leads to 100% apoptosis in MCF-7 cells, even
after the removal of the PST
MCF-7 cells were treated for 48 hours with PST and then given fresh media. After 48 hours, cells
were split and trypan blue was used to measure the number of viable MCF-7 cells, as described.
Cells were spilt and counted two additional times at 48 hour intervals. Results were calculated
using data from three separate sets of experiments.
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4.5 The effect of Pancratistatin treatment on protease activity
4.5.1 Proteasome and caspase-3 activation during apoptosis of cancerous
cells following, Pancratistatin treatment
As we have seen, caspases, such as caspase-3, are an integral part of
the apoptotic pathway (Ashkenazi and Dixit 1998). In addition to the caspases,
another enzymatic pathway called the ubiquitin-proteasome pathway mediates
the protein degradation that is associated with apoptosis (Rodgers 2002).
Caspase-3 and proteasome protease assays were conducted in order to verify
that apoptosis was induced in the cancerous cell lines. The cells were grown,
treated, and assays for proteasome and caspase-3 activity were conducted.
After 3 and 6 hours of treatment, SHSY-5Y cells treated with PST
exhibited a slight increase in the amount of caspase-3 (figure 4-20a) and
proteasome activity (figure 4-20b). After 24 hours of treatment with PST, both
the caspase-3 and proteasome activity rose to 171% of control and 300% of
control, respectively. An ANOVA indicated that the control and 24 hour values
were significantly different for both caspase-3 and proteasome (p = 0.00003 and
p=0.0002, respectively).
The other cancerous cell lines examined produced similar results. MCF-7
cells treated with PST show a significant increase in the activation of both
caspase-3 and proteasome activity after 96 hours (figure 4-21a and b).
Caspase-3 and proteasome activity in the other two types of cancerous cells:
Hs578-T (figure 4-22a and b) and HT-29 (figure 4-23a and b) exhibit the same
pattern. An ANOVA indicated that the MCF-7 control and 96 hour values were
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Figure 4-20a: Caspase-3 is activated in SHSY-5Y cells treated
by Pancratistatin
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Caspase-3 is activated in SHSY-5Y cells treated by Pancratistatin

SHSY-5Y cells were treated with PST and a caspase-3 assay was used to measure the
caspase-3 activity, as described. Results were calculated per microgram of protein as a
percentage of the control values and standard deviations were calculated using data from three
separate sets of experiments.

Figure 4-20b: Proteasome is activated in SHSY-5Y cells
treated by Pancratistatin
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Proteasome is activated in SHSY-5Y cells treated by Pancratistatin

SHSY-5Y cells were treated with PST and a proteasome assay was used to measure the
proteasome activity, as described. Results were calculated per microgram of protein as a
percentage of the control values and standard deviations were calculated using data from three
separate sets of experiments.
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Figure 4-21 a: Caspase-3 is activated in MCF-7 cells treated by
Pancratistatin
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Caspase-3 is activated in MCF-7 cells treated by Pancratistatin

MCF-7 cells were treated with PST and a caspase-3 assay was used to measure the
caspase-3 activity, as described. Results were calculated per microgram of protein as a
percentage of the control values and standard deviations were calculated using data from three
separate sets of experiments.

Figure 4-21 b: Proteasome is activated in MCF-7 cells treated
by Pancratistatin
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Proteasome is activated in MCF-7 cells treated by Pancratistatin

MCF-7 cells were treated with PST and a proteasome assay was used to measure the
proteasome activity, as described. Results were calculated per microgram of protein as a
percentage of the control values and standard deviations were calculated using data from three
separate sets of experiments.
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Figure 4-22a: Caspase-3 is activated in Hs578-T cells
treated by Pancratistatin
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Caspase-3 is activated in Hs578-T cells treated by Pancratistatin

Hs578-T cells were treated with PST and a caspase-3 assay was used to measure the
caspase-3 activity, as described. Results were calculated per microgram of protein as a
percentage of the control values and standard deviations were calculated using data from three
separate sets of experiments.

Figure 4-22b: Proteasome is activated in Hs578-T cells
treated by Pancratistatin
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Proteasome is activated in Hs578-T cells treated by Pancratistatin

Hs578-T cells were treated with PST and a proteasome assay was used to measure the
proteasome activity, as described. Results were calculated per microgram of protein as a
percentage of the control values and standard deviations were calculated using data from three
separate sets of experiments.
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significantly different for both caspase-3 and proteasome (p = 0.004067 and
p=0.007969, respectively). The ANOVA also indicated that the control and 96
hour values for)Hs578-T (p = 0.000381 and p=0.001457, respectively) and HT-29
(p=0.01077 and p=0.001457, respectively) were significantly different.

The

results of these assays illustrate the ability of PST to induce biochemical changes
in cancerous cells.

4.5.2 Proteasome and caspase-3 are not activated in non-cancerous cells
following PST treatment
Similar treatments and assays were preformed using the normal cell lines:
NHF, Hs578-Bst, CCD-18Co, and HMEC cells. Even after NHF cells are treated
with PST for 24 hours, both the caspase-3 (figure 4-24a) and proteasome (figure
4-24b) activities remained identical to the control. An ANOVA indicated that the
values were not significantly different from the control values (p>0.05).

The

Hs578-Bst, CCD-18Co, and HMEC cells treated with PST for 24 hours all had
comparable results (figure 4-25a, b, 4-26a, b, 4-27a, and b).

None of these

values were significantly different from the control values (p>0.05).

4.5.3 Caspase-3 inhibition does not prevent apoptosis in PST treated
cancer cells
In order to determine if PST-induced apoptosis of cancerous cells is
caspase-3 dependent, a caspase-3 inhibition assay was preformed using DEVDfmk. MCF-7 and Hs578-T cells were pre-treated with DEVD-fmk and treated with
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Figure 4-23a: Caspase-3 is activated in HT-29 cells
treated by Pancratistatin
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Caspase-3 is activated in HT-29 cells treated by Pancratistatin

HT-29 cells were treated with PST and a caspase-3 assay was used to measure the
caspase-3 activity, as described. Results were calculated per microgram of protein as a
percentage of the control values and standard deviations were calculated using data from three
separate sets of experiments.

Figure 4-23b: Proteasome is activated in HT-29 cells treated
by Pancratistatin
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Proteasome is activated in HT-29 cells treated by Pancratistatin

HT-29 cells were treated with PST and a proteasome assay was used to measure the
proteasome activity, as described. Results were calculated per microgram of protein as a
percentage of the control values and standard deviations were calculated using data from three
separate sets of experiments.
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Figure 4-24a: Caspase-3 is not activated in NHF cells treated
by Pancratistatin
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Caspase-3 is not activated in NHF cells treated by Pancratistatin

NHF cells were treated with PST and a caspase-3 assay was used to measure the
caspase-3 activity, as described. Results were calculated per microgram of protein as a ■
percentage of the control values and standard deviations were calculated using data from three
separate sets of experiments.

Figure 4-24b: Proteasome is not activated in NHF cells
treated by Pancratistatin
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Figure 4-24b:
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Proteasome is not activated in NHF cells treated by Pancratistatin

NHF cells were treated with PST and a proteasome assay was used to measure the proteasome
activity, as described. Results were calculated per microgram of protein as a percentage of the
control values and standard deviations were calculated using data from three separate sets of
experiments.
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Figure 4-25a: Caspase-3 is not activated in Hs578-Bst cells
treated by Pancratistatin
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Caspase-3 is not activated in Hs578-Bst cells treated by Pancratistatin

Hs578-T cells were treated with PST and a caspase-3 assay was used to measure the
caspase-3 activity, as described. Results were calculated per microgram of protein as a
percentage of the control values and standard deviations were calculated using data from three
separate sets of experiments.

Figure 4-25b: Proteasome is not activated in Hs578-Bst cells
treated by Pancratistatin
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Proteasome is not activated in Hs578-Bst cells treated by Pancratistatin

Hs578-Bst cells were treated with PST and a proteasome assay was used to measure the
proteasome activity, as described. Results were calculated per microgram of protein as a
percentage of the control values and standard deviations were calculated using data from three
separate sets of experiments.
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Figure 4-26a: Caspase-3 is not activated in CCD-18Co cells
treated by Pancratistatin
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Caspase-3 is not activated in CCD-18Co cells treated by Pancratistatin

CCD-18Co cells were treated with PST and a caspase-3 assay was used to measure the
caspase-3 activity, as described. Results were calculated per microgram of protein as a
percentage of the control values and standard deviations were calculated using data from three
separate sets of experiments.

Figure 4-26b: Proteasome is not activated in CCD-18Co cells
treated by Pancratistatin

_

2
C
o
o

200%

180%

•g 160%
^

140%

.5!

120%,

c
2

Q. 100%

■6
O)

80%

g
c
Jj
in

60%

3

§
3

u-

40%
20%

0%
C

Figure 4-26b:

24hr

48hr

96hr

Proteasome is not activated in CCD-18Co cells treated by Pancratistatin

CCD-18Co cells were treated with PST and a proteasome assay was used to measure the
proteasome activity, as described. Results were calculated per microgram of protein as a
percentage of the control values and standard deviations were calculated using data from three
separate sets of experiments.
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Figure 4-27a: Caspase-3 is not activated in HMEC cells
treated by Pancratistatin
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Caspase-3 is not activated in HMEC cells treated by Pancratistatin

HMEC cells were treated with PST and a caspase-3 assay was used to measure the
caspase-3 activity, as described. Results were calculated per microgram of protein as a
percentage of the control values and standard deviations were calculated using data from three
separate sets of experiments.

Figure 4-27b: Proteasome is not activated in HMEC cells
treated by Pancratistatin
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Proteasome is not activated in HMEC cells treated by Pancratistatin

HT-29 cells were treated with PST and a proteasome assay was used to measure the
proteasome activity, as described. Results were calculated per microgram of protein as a
percentage of the control values and standard deviations were calculated using data from three
separate sets of experiments.
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PST. The nuclear condensation and morphology were visualized using Hoechst
33342 dye. Figure 4-28a and b show that after 48 and 96 hours the MCF-7 cells
treated with P$T with or without the DEVD-fmk pre-treatment have the same
number of apoptotic cells.
results.

Hs578-T cells (figure 4-29a and b) show the same

This indicates that PST induced apoptosis of cancerous cells may be

caspase-3 independent and, do to the release of AIF and the induction of
caspase-3 independent apoptosis, that the intrinsic pathway may be involved.

4.6 Role of the mitochondria in PST induced apoptosis
Mitochondrial dysfunction has been associated with apoptotic cell death.
In order to evaluate the role of the mitochondria in Pancratistatinrinduced
apoptosis of cancer cells, we looked at ROS generation, MMP and concentration
of ATP following Pancratistatin treatment.

4.6.1 Reactive oxygen species generation is induced by Pancratistatin in
cancerous cells
An increase in reactive oxygen species (ROS) has been associated with
mitochondrial dysfunction during apoptotic cell death.

In order to investigate if

PST treatment causes an increase in the amount of ROS, a measurement of the
relative amount of ROS was carried out using a fluorometric assay.

Both

cancerous and non-cancerous cells were treated with PST and the ROS was
measured, as described.
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Figure 4-28a: Caspase-3 inhibition does not prevent
apoptosis in MCF-7 cells treated with PST
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Figure 4-28a: Caspase-3 inhibition does not prevent apoptosis in MCF-7 cells
treated with PST
MCF-7 cells were either pre-treated with DEVD-fmk or treated directly with 1pM of PST, as
described. Cells were stained with Hoechst 33342 dye to examine nuclear morphology and
fluorescent pictures were taken at 400x magnification. Nuclear condensation is evident in cells
with bright, condensed, and rounded nuclei.

Figure 4-28b: Caspase-3 inhibition does not decrease the
apoptotic index in MCF-7 cells treated with PST

Control
3PST

HDEVD-Fmk + PST

Figure 4-28b: Caspase-3 inhibition does not decrease the apoptotic index in MCF-7 cells
treated with PST
MCF-7 cells were treated and stained as in a. The number of apoptotic nuclei was counted and
the average percentage of apoptotic cells was calculated from a minimum of 500 cells. Standard
errors were calculated using data from three separate sets of experiments.
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Figure 4-29a: Caspase-3 inhibition does not prevent
apoptosis in Hs578-T cells treated with Pancratistatin
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Figure 4-29a: Caspase-3 inhibition does not prevent apoptosis in Hs578-T cells
treated with Pancratistatin
Hs578-T cells were either pre-treated with DEVD-fmk or treated directly with 1pM of PST, as
described. Cells were stained with Hoechst 33342 dye to examine nuclear morphology and
fluorescent pictures were taken at 400x magnification. Nuclear condensation is evident in cells
with bright, condensed, and rounded nuclei.

Figure 4-29b: Caspase-3 inhibition does not decrease the
apoptotic index in Hs578-T ceils treated with Pancratistatin
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Figure 4-29b: Caspase-3 inhibition does not decrease the apoptotic index in Hs578-T
cells treated with Pancratistatin
Hs578-T cells were treated and stained as in a. The number of apoptotic nuclei was counted and
the average percentage of apoptotic cells was calculated from a minimum of 500 cells. Standard
errors were calculated using data from three separate sets of experiments.
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Figure 4-30 depicts the amount of ROS generation in SHSY-5Y cells
treated with PST. The amount of ROS in SHSY-5Y cells is significantly higher
than that of the control after only 3 hours of PST treatment. The amount of ROS
continues to rise with 6 and 24 hour (p=0.0000001) treatments.
MCF-7 (Figure 4-31), Hs578-T (Figure 4-32), and HT-29 (Figure 4-33)
cells treated with PST also show relatively early and significant increases in the
amounts of cellular ROS, as compared to the control cells. An ANOVA indicated
that the amount of ROS in the treated cells was significantly different from the
control values after 48 hours in MCF-7 cells (p=0.000005), Hs578-T cells
(p=0.000002), and HT-29 (p=0.000929).

These results indicate that the

mitochondria of cancerous cells may be permeablized during PST treatment.
All of the non-cancerous cells tested do not show any significant PST
induced increases in the amount of ROS from the control cells. NHF cells have a
minimal increase in ROS (figure 4-34) in the 3 and 6 hour treatments, but after a
24 hour treatment the increased ROS is no longer present and the levels are the
same as the control cells.

Hs578-Bst (figure 4-35), CCD-18Co (figure 4-36), and

HMEC (figure 4-37) cells treated with PST have ROS levels approximately the
same as control cells.

An ANOVA indicated that in all the non-cancerous cells,

values were not significantly different from control values (p>0.05).
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Figure 4-30: Reactive oxygen species generation in SHSY-5Y
cells treated by Pancratistatin
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Figure 4-30: Reactive oxygen species generation in SHSY-5Y cells treated by
Pancratistatin
SHSY-5Y cells were treated with PST and DCFDA was used to measure the total cell ROS
generation, as described. Results were calculated per microgram of protein as a percentage of
the control using data from three separate sets of experiments.

Figure 4-31: Reactive oxygen species generation in MCF-7
cells treated by Pancratistatin
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Reactive oxygen species generation in MCF-7 cells treated by Pancratistatin

M C F -7 cells were treated with PST and DCFDA was used to measure the total cell ROS
generation, as described. Results were calculated per microgram of protein as a percentage of
the control using data from three separate sets of experiments.
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Figure 4-32: Reactive oxygen species generation in Hs578-T
cells treated by Pancratistatin
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Figure 4-32: Reactive oxygen species generation in Hs578-T cells treated by
Pancratistatin
H s578-T cells were treated with PST and DCFDA was used to measure the total cell ROS
generation, as described. Results were calculated per microgram of protein as a percentage of
the control using data from three separate sets of experiments.

Figure 4-33: Reactive oxygen species generation in HT-29
cells treated by Pancratistatin
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Figure 4-33: Reactive oxygen species generation in Hs578-T cells treated by
Pancratistatin
H T -29 cells were treated with PST and DCFDA was used to measure the total cell ROS
generation, as described. Results were calculated per microgram of protein as a percentage of
the control using data from three separate sets of experiments.
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Figure 4-34: Reactive oxygen species is not increased in NHF
cells treated by Pancratistatin
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Figure 4-34: Reactive oxygen species is not increased in NHF cells treated by
Pancratistatin
NHF cells were treated with PST and DCFDA was used to measure the total cell ROS
generation, as described. Results were calculated per microgram of protein as a percentage of
the control using data from three separate sets of experiments.

Figure 4-35: Reactive oxygen species is not increased in
HMEC cells treated by Pancratistatin
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Figure 4-35: Reactive oxygen species is not increased in HMEC cells treated by
Pancratistatin
HMEC cells were treated with PST and DCFDA was used to measure the total cell ROS
generation, as described. Results were calculated per microgram of protein as a percentage of
the control using data from three separate sets of experiments.

85

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 4-36: Reactive oxygen species is not increased in
Hs578-Bst cells treated by Pancratistatin
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Figure 4-36: Reactive oxygen species is not increased in Hs578-Bst cells treated by
Pancratistatin
Hs578-Bst cells were treated with PST and DCFDA was used to measure the total cell ROS
generation, as described. Results were calculated per microgram of protein as a percentage of
the control using data from three separate sets of experiments.

Figure 4-37: Reactive oxygen species is not increased in
CCD-18Co cells treated by Pancratistatin
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Figure 4-37: Reactive oxygen species is not increased in CCD-18Co cells treated by
Pancratistatin
CCD-18Co cells were treated with PST and DCFDA was used to measure the total cell ROS
generation, as described. Results were calculated per microgram of protein as a percentage of
the control using data from three separate sets of experiments.
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4.6.2 Mitochondrial membrane permeability changes in cancer cells
following Pancratistatin treatment

An increase in the amount of ROS may be indicative of mitochondrial
dysfunction (Somayajulu et at. 2005).

In order to examine the effects of PST

treatment on the mitochondria, several assays were carried out. Mitochondrial
membrane permeability (MMP) can be visualized by two dyes: mitotracker red
and JC-1.

In addition, MMP and caspase-3 activation can be simultaneously

detected using the Mito-casp assay.
SHSY-5Y, MCF-7, Hs578-T, and HT-29 cells were treated with PST, as
previously described, and cells were stained with mitotracker red or JC-1 dye. In
addition, the relation of between mitochondrial membrane permeablization and
caspase-3 activation was examined in MCF-7 cells using the Mito-casp assay.
Figure 4-38a and b illustrate an increase in mitochondrial membrane
permeability in SHSY-5Y cells after only three hours of PST treatment (using JC1 and mitotracker red dyes, respectively). The permeability continues to increase
following 6 and 24 hour treatments.
MCF-7 cells stained with JC-1 still have their mitochondrial membrane
potential intact after 24 hours of PST treatment (figure 4-39a). However, after 48
hours, no healthy mitochondria can be visualized. Mitotracker red staining can
be seen in figure 4-39b.

From these results we can see a decrease in the

amount of red fluorescence after 24 hours, but a full loss of staining does not
occur until 48 hours of treatment.

Figure 4-39c illustrates that mitochondrial

membrane potential loss occurs before the increase in caspase activation,
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Figure 4-38a: Mitochondrial membrane permeability in
SHSY-5Y cells treated by Pancratistatin: JC-1 staining
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Figure 4-38a: Mitochondrial membrane permeability in SHSY-5Y cells treated by
Pancratistatin: JC-1 staining
SHSY-5Y cells were treated with PST and JC-1 dye was applied to the cells to examine
mitochondrial membrane potential. Fluorescent pictures were taken at 400x magnification.
Bright red florescence is indicative of healthy mitochondria with intact membrane potential.

Figure 4-38b: Mitochondrial membrane permeability in
SHSY-5Y cells treated by Pancratistatin:
Mitotracker Red staining
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3hrs

6hrs

24hrs

Figure 4-38b: Mitochondrial membrane permeability in SHSY-5Y cells treated by
Pancratistatin: Mitotracker-red staining
SHSY-5Y cells were treated with PST and mitotracker red dye was applied to the cells to
examine mitochondrial membrane potential. Pictures were taken at 400x magnification. Bright
fluorescence is indicative of healthy mitochondria, while diffuse staining is indicative of a loss in
mitochondrial membrane potential.
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Figure 4-39a: Mitochondrial membrane permeability in
MCF-7 cells treated by Pancratistatin: JC-1 staining
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Figure 4-39a: Mitochondrial membrane permeability in MCF-7 cells treated by
Pancratistatin: JC-1 staining
MCF-7 cells were treated with PST and JC-1 dye was applied to the cells to examine
mitochondrial membrane potential. Fluorescent pictures were taken at 400x magnification.
Bright red florescence is indicative of healthy mitochondria with intact membrane potential.

Figure 4-39b: Mitochondrial membrane permeability in
MCF-7 cells treated by Pancratistatin:
Mitotracker Red staining
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Figure 4-39b: Mitochondrial membrane permeability in MCF-7 cells treated by
Pancratistatin: Mitotracker-red staining
MCF-7 cells were treated with PST and mitotracker red dye was applied to the cells to examine
mitochondrial membrane potential. Pictures were taken at 400x magnification. Bright
fluorescence is indicative of healthy mitochondria, while diffuse staining is indicative of a loss in
mitochondrial membrane potential.
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Figure 4-39c: Mitochondrial membrane permeability and
caspase-3 activation in MCF-7 cells treated
by Pancratistatin: Mito-casp Assay
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Figure 4-39c: Mintochondrial membrane permeability and caspase activation in MCF-7
cells treated Pancratistatin: Mito-casp Assay
MCF-7 cells were treated with PST and a mito-casp assay was used to measure the activation of
caspases and the loss of mitochondrial membrane potential, as described. Results were
calculated per 10 000 cells as a percentage of the control using data from three separate sets of
experiments.
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demonstrating that indeed, the mitochondria may be the target of PST in
cancerous cells. When stained with JC-1, the Hs578-T and HT-29 cells show a
similar pattern to the MCF-7 cells (figure 4-40 and 4-41, respectively).
Normal, non-cancerous cells were also treated with PST and stained with
JC-1 dye. Treatment of NHF cells with PST for 96 hours, results in no change in
the mitochondrial membrane permeability as visualized by JC-1 (figure 4-42).
HMEC cells treated for 96 hours show the same pattern (figure 4-43).
Additionally,

Hs578-Bst

and CCD-18Co

cells

stained

with

JC-1

have

mitochondria that can be easily visualized (figure 4-44 and 4-45) after 72 hours of
treatment. These results indicate that even after several days of PST treatment,
all of the normal cells tested still have intact mitochondrial membrane potential.

4.6.3 Effect of Pancratistatin treatment on cellular ATP concentration in
cancerous and normal cells
A decrease in total cellular ATP concentration can be indicative of
mitochondrial dysfunction (Orrenius 2004). In order to evaluate if PST causes a
loss in ATP production, a luciferin-luciferase assay was conducted using the
cytoplasmic extracts of both cancerous and normal cells.
After three hours of treatment, figure 4-46 demonstrates that SHSY-5Y
cells show a considerable decrease in the amount of ATP present in the cell.
Another significant decrease in the amount of ATP is seen following a 24 hour
treatment with PST (p=0.000001).
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Figure 4-40: Mitochondrial membrane permeability in
Hs578-T cells treated by Pancratistatin: JC-1 staining
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Figure 4-40: Mitochondrial membrane permeability in Hs578-T cells treated by
Pancratistatin: JC-1 staining
Hs578-T cells were treated with PST and JC-1 dye was applied to the cells to examine
mitochondrial membrane potential. Fluorescent pictures were taken at 400x magnification.
Bright red florescence is indicative of healthy mitochondria with intact membrane potential.

Figure 4-41: Mitochondrial membrane permeability in
HT-29 cells treated by Pancratistatin: JC-1 staining
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Figure 4-41: Mitochondrial membrane permeability in HT-29 cells treated by
Pancratistatin: JC-1 staining
HT-29 cells were treated with PST and JC-1 dye was applied to the cells to examine
mitochondrial membrane potential. Fluorescent pictures were taken at 400x magnification.
Bright red florescence is indicative of healthy mitochondria with intact membrane potential.
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Figure 4-42: Mitochondrial membrane permeability in
NHF cells treated by Pancratistatin: JC-1 staining
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Figure 4-42: Mitochondrial membrane permeability in NHF cells treated by Pancratistatin:
JC-1 staining
NHF cells were treated with PST and JC-1 dye was applied to the cells to examine mitochondrial
membrane potential. Fluorescent pictures were taken at 400x magnification. Bright red
florescence is indicative of healthy mitochondria with intact membrane potential.

Figure 4-43: Mitochondrial membrane permeability in
HMEC cells treated by Pancratistatin: JC-1 staining
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Figure 4-43: Mitochondrial membrane permeability in HMEC cells treated by
Pancratistatin: JC-1 staining
HMEC cells were treated with PST and JC-1 dye was applied to the cells to examine
mitochondrial membrane potential. Fluorescent pictures were taken at 400x magnification.
Bright red florescence is indicative of healthy mitochondria with intact membrane potential.
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Figure 4-44: Mitochondrial membrane permeability in
Hs578-Bst cells treated by Pancratistatin: JC-1 staining
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Figure 4-44: Mitochondrial membrane permeability in Hs578-Bst cells treated by
Pancratistatin: JC-1 staining
Hs578-Bst cells were treated with PST and JC-1 dye was applied to the cells to examine
mitochondrial membrane potential. Fluorescent pictures were taken at 400x magnification.
Bright red florescence is indicative of healthy mitochondria with intact membrane potential.

Figure 4-45: Mitochondrial membrane permeability in
CCD-18Co cells treated by Pancratistatin: JC-1 staining

Control

72 hrs PST

Figure 4-45: Mitochondrial membrane permeability in CCD-18Co cells treated by
Pancratistatin: JC-1 staining
CCD-18Co cells were treated with PST and JC-1 dye was applied to the cells to examine
mitochondrial membrane potential. Fluorescent pictures were taken at 400x magnification.
Bright red florescence is indicative of healthy mitochondria with intact membrane potential.
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Figure 4-46: ATP concentration in SHSY-5Y cells treated by
Pancratistatin

X

120% T

100% -

*8

80%

I

60%

l
O)

D

40%

20 %

0%
C

Figure 4-46:

3hr

6hr

24hr

ATP concentration in SHSY-5Y cells treated by Pancratistatin

SHSY-5Y celis were treated with PST and an ATP assay was conducted in order to estimate the
amount of ATP, as described. Results were calculated per microgram of protein as a percentage
of the control using data from three separate sets of experiments.
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MCF-7 cells require a longer PST treatment to induce this drop in the
cellular levels of ATP (figure 4-47). After 24 hours, there is a decrease in the
amount of cellular ATP (p=0.000003).

Hs578-T and HT-29 cells also take 24

hours of PST treatment to loose a significant amount of cellular ATP
concentration (figure 4-48 and 4-49, respectively).
In order to see if normal cells are equally affected by PST, the same assay
was used to test the ATP concentration in NHF, HMEC, Hs578-Bst, and CCD18Co cells following PST treatment. Figure 4-50 illustrates that there is virtually
no drop in ATP concentration of NHF cells after 3, 6, and 24 hour treatments
(p>0.05). HMEC cells treated with PST (figure 4-51) do not show any significant
decrease in the amount of ATP (p>0.05).

Hs578-Bst (figure 4-52) and CCD-

18Co (figure 4-53) cells show the same pattern.
Taken together, these results indicate that Pancratistatin treatment
effectively induces mitochondrial dysfunction, mitochondrial membrane potential
collapse, ROS production, and a decrease in the cellular levels of ATP in
cancerous cells. Non-cancerous cells do not show these effects.
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Figure 4-47: ATP concentration in MCF-7 cells treated by
Pancratistatin

_

120%

o

L.

o
o 100%
o
0s*

80%

C
*5

60%

1o>

40%

"

20%

0

3

57
i^=* o%
C

Figure 4-47:

24hr
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96hr

ATP concentration in MCF-7 cells treated by Pancratistatin

MCF-7 cells were treated with PST and an ATP assay was conducted in order to estimate the
amount of ATP, as described. Results were calculated per microgram of protein as a percentage
of the control using data from three separate sets of experiments.

Figure 4-48: ATP concentration in Hs578-T cells treated by
Pancratistatin
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Figure 4-48:
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96hr

ATP concentration in Hs578-T cells treated by Pancratistatin

Hs578-T cells were treated with PST and an ATP assay was conducted in order to estimate the
amount of ATP, as described. Results were calculated per microgram of protein as a percentage
of the control using data from three separate sets of experiments.
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Figure 4-49: ATP concentration in HT-29 cells treated by
Pancratistatin
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Figure 4-49:

48hr

96hr

ATP concentration in HT-29 cells treated by Pancratistatin

HT-29 cells were treated with PST and an ATP assay was conducted in order to estimate the
amount of ATP, as described. Results were calculated per microgram of protein as a percentage
of the control using data from three separate sets of experiments.

Figure 4-50: ATP concentration in NHF cells treated by
Pancratistatin
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Figure 4-50:
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96hr

ATP concentration in NHF cells treated by Pancratistatin

NHF cells were treated with PST and an ATP assay was conducted in order to estimate the
amount of ATP, as described. Results were calculated per microgram of protein as a percentage
of the control using data from three separate sets of experiments.
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Figure 4-51: ATP concentration in HMEC cells treated by
Pancratistatin
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ATP concentration in HMEC cells treated by Pancratistatin

HMEC cells were treated with PST and an ATP assay was conducted in order to estimate the
amount of ATP, as described. Results were calculated per microgram of protein as a percentage
of the control using data from three separate sets of experiments.

Figure 4-52: ATP concentration in Hs578-Bst cells treated by
Pancratistatin
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Figure 4-52:

96hr

ATP concentration in Hs578-Bst cells treated by Pancratistatin

Hs578-Bst cells were treated with PST and an ATP assay was conducted in order to estimate the
amount of ATP, as described. Results were calculated per microgram of protein as a percentage
of the control using data from three separate sets of experiments.
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Figure 4-53: ATP concentration in CCD-18Co cells treated by
Pancratistatin

200%
S

180%

O 160%
o

140%

I

100%

24hr

Figure 4-53:
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ATP concentration in CCD-18Co cells treated by Pancratistatin

CCD-18Co cells were treated with PST and an ATP assay was conducted in order to estimate the
amount of ATP, as described. Results were calculated per microgram of protein as a percentage
of the control using data from three separate sets of experiments.
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4.7 The effect of direct Pancratistatin treatment on isolated mitochondria

Because PST induced mitochondrial dysfunction early on in the apoptotic
pathway, we investigated the effect of Pancratistatin treatment directly on the
mitochondria.

In order to determine

if Pancratistatin

itself can cause

mitochondrial dysfunction, mitochondria were isolated from untreated cancerous
and non-cancerous cell lines and treated directly with Pancratistatin, as
described. Additionally, isolated mitochondria from several cell lines were pre
treated with water soluble C0 Q 10, a known anti-oxidant that has been shown to
offer mitochondrial protection (McCarthy 2004).

4.7.1 Mitochondria isolated from cancerous cells are sensitive to PST
treatment
Figure

4-54

illustrates

the

effect

of

PST

on

isolated

SHSY-5Y

mitochondria. After 30 minutes of PST treatment, SHSY-5Y mitochondria show a
significant increase in the amount of mitochondrial ROS with respect to control
(p=0.006575). Mitochondria from SHSY-5Y cells that were pre-treated with
CoQ-io had less mitochondrial ROS present than those that were treated and had
comparable levels of ROS with control (p>0.05).
Isolated MCF-7 mitochondria treated with PST for 30 minutes show a
rapid increase in the amount of ROS (-50% ) (p=0.000001), but after 2 hours of
PST treatment, the ROS rises only another 17% (figure 4-55).

Isolated Hs578-T

mitochondria treated with PST show a significant increase in the amount of
mitochondrial ROS after 30 minutes with PST (figure 4-56) (p=0.000106). HT-29
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Figure 4-54: ROS in isolated SHSY-5Y mitochondria treated
with Pancratistatin
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ROS in isolated SHSY-5Y mitochondria treated with Pancratistatin

Mitochondria from untreated SHSY-5Y cells were isolated and treated with PST in the presence
or absence of CoQi0, as described. The mitochondrial ROS was measured using PHPA and
HRP. Results were calculated per microgram of protein and standard deviations were calculated
using data from three separate sets of experiments.

Figure 4-55: ROS in isolated MCF-7 mitochondria treated with
Pancratistatin
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Figure 4-55:

.5hrs PST
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2hrs PST

ROS in isolated MCF-7 mitochondria treated with Pancratistatin

Mitochondria from untreated MCF-7 cells were isolated and treated with PST, as described. The
mitochondrial ROS was measured using PHPA and HRP. Results were calculated per
microgram of protein and standard deviations were calculated using data from three separate
sets of experiments.
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Figure 4-56: ROS in isolated Hs578-T mitochondria treated
with Pancratistatin
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ROS in isolated Hs578-T mitochondria treated with Pancratistatin

Mitochondria from untreated Hs578-T cells were isolated and treated with PST in the presence or
absence of CoQ10, as described. The mitochondrial ROS was measured using PHPA and HRP.
Results were calculated per microgram of protein and standard deviations were calculated using
data from three separate sets of experiments.
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mitochondria treated with PST for 30 minutes show the same results (figure 4-57)
(p=0.010668).
l
4.7.2 Mitochondria isolated from non-cancerous cells are not affected by
Pancratistatin treatment
Figure 4-58 shows the results of PST treatment of isolated NHF
mitochondria for up to 2 hours.

Most significantly, the treated and control

mitochondria had the same levels of mitochondrial ROS, thus NHF mitochondria
do not seem affected by PST treatment (p>0.05).

Those cells that were pre

treated with CoQ10 have levels of ROS slightly below those of the control and
treated cells (p>0.05). The same result is replicated by HMEC, Hs578-Bst, and
CCD-18Co mitochondria in figures 4-59, 60, and 61, respectively. These results
indicate that the mitochondria of normal cells are not suffering from damaging
oxidative stress following PST treatment.
Together these results imply that PST treatment can directly and
specifically target isolated mitochondria of cancerous cells, while leaving normal,
non-cancerous mitochondria unharmed.
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Figure 4-57: ROS in isolated HT-29 mitochondria treated with
Pancratistatin

BMW

■
W B

mm
m tm

1
PST

Figure 4-57:

r■

■
I
■ I1
11

,

PST+CoQ 10

ROS in isolated HT-29 mitochondria treated with Pancratistatin

Mitochondria from untreated HT-29 cells were isolated and treated with PST in the presence or
absence of CoQ10, as described. The mitochondrial ROS was measured using PHPA and HRP.
Results were calculated per microgram of protein and standard deviations were calculated using
data from three separate sets of experiments.

Figure 4-58: ROS in isolated NHF mitochondria treated with
Pancratistatin
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ROS in isolated NHF mitochondria treated with Pancratistatin

Mitochondria from untreated NHF cells were isolated and treated with PST in the presence or
absence of CoQ10, as described. The mitochondrial ROS was measured using PHPA and HRP.
Results were calculated per microgram of protein and standard deviations were calculated using
data from three separate sets of experiments.
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Figure 4-59: ROS in isolated HMEC mitochondria treated with
Pancratistatin
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Figure 4-59:

ROS in isolated HMEC mitochondria treated with Pancratistatin

Mitochondria from untreated HMEC cells were isolated and treated with PST in the presence or
absence of CoQ10, as described. The mitochondrial ROS was measured using PHPA and HRP.
Results were calculated per microgram of protein and standard deviations were calculated using
data from three separate sets of experiments.

Figure 4-60: ROS in isolated Hs578-Bst mitochondria treated
with Pancratistatin
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Figure 4-60:

ROS in isolated Hs578-Bst mitochondria treated with Pancratistatin

Mitochondria from untreated Hs578-Bst cells were isolated and treated with PST in the presence
or absence of CoQ10, as described. The mitochondrial ROS was measured using PHPA and
HRP. Results were calculated per microgram of protein and standard deviations were calculated
using data from three separate sets of experiments.
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Figure 4-61: ROS in isolated CCD-18Co mitochondria treated
with Pancratistatin
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Figure 4-61:

ROS in isolated CCD-18Co mitochondria treated with Pancratistatin

Mitochondria from untreated CCD-18Co cells were isolated and treated with PST in the presence
or absence of C0 Q 10 , as described. The mitochondrial ROS was measured using PHPA and
HRP. Results were calculated per microgram of protein and standard deviations were calculated
using data from three separate sets of experiments.
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4.8 Single domain anti-bodies against BAX do not protect cancerous cells
from PST induced apoptosis
BAX, or BCL2-associated X protein, forms homo-dimers that migrate to
the mitochondria when there is internal damage to the cell (i.e. an increase in
ROS).

This can lead to the permeablization of the mitochondrial membrane

(Leist and Jaattela 2001).

Our laboratory, in association with NRC, has

developed single domain anti-bodies (sdAB) against BAX that can prevent H2O2
induced apoptosis (unpublished results).
To determine if PST induced apoptosis could be due to increased
oxidative stress or BAX activation, SHSY-5Y cells were transfected with sdAB
against BAX, as previously described. Cells were then treated with PST for 48
hours and stained with Hoechst-33342. Figure 4-62a shows cells transfected with
sdAB against BAX that are treated with Pancratistatin undergo apoptosis, as
depected by nuclear condensation. Figure 4-62b depicts that sdAB transfected
cells treated with PST show levels of apoptosis similar to non-transfected PSTtreated SHSY-5Y cells. These results indicate that PST may inducing apoptosis
in a BAX-independent manor and confirm that PST may be acting directly on the
mitochondria.
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Figure 4-62a: sdAB against BAX do not protect SHSY-5Y cells
treated by Pancratistatin

Figure 4-62a:
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sdAB against BAX do not protect SHSY-5Y cells treated by Pancratistatin

SHSY-5Y cells transfected with sdAB against BAX were treated with IpM of PST and stained
with Hoechst 33342 dye to examine nuclear morphology. Fluorescent pictures were taken at
400x magnification. Nuclear condensation is evident in cells with bright, condensed, and rounded
nuclei.

Figure 4-62b: sdAB against BAX do not lower the apoptotic
index of SHSY-5Y cells treated by Pancratistatin
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Figure 4-62b: sdAB against BAX do not lower the apoptotic index of SHSY-5Y cells
treated by Pancratistatin
SHSY-5Y cells transfected with sdAB against BAX were treated with 1pM PST and stained with
Hoechst 33342 dye. The number of apoptotic nuclei was counted and the average percentage of
apoptotic cells was calculated from a minimum of 500 cells. Standard errors were calculated
using data from a minimum of three separate sets of experiments.
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CHAPTER 5: DISCUSSION
Current cancer research focuses on treatments that can selectively rid the
body of cancerous cells, while leaving the non-cancerous cells unharmed. In this
study, the anti-cancer potential of Pancratistatin is evaluated using cell culture
models.

In addition, this study has provided a look at the mechanism by which

Pancratistatin induces apoptosis in several cancerous cell lines.

5.1 Pancratistatin effectively and specifically induces apoptosis in
cancerous cells
The induction of apoptosis specifically in cancerous cells would allow the
body to kill cancerous cells without causing inflammation or damage to nearby
tissues. In order to evaluate the anti-cancer potential of Pancratistatin, the ability
of this natural compound to induce apoptosis only in cancerous cells was
evaluated by monitoring nuclear condensation, phosphatidyl serine flipping
across the plasma membrane, and

DNA degradation.

This study has

demonstrated that Pancratistatin can effectively induce apoptosis in several
types of cancerous cells at relatively low concentrations without causing any
adverse effects on normal cells.
Initially, the effectiveness of PST was evaluated in several cancerous cell
lines. In neuroblastoma (SHSY-5Y) cells treated with 1pM of PST, the majority of
cells were apoptotic after 24 hours of treatment. Breast cancer cells, both MCF-7
and Hs578-T, and colon cancer cells (HT-29) required 72 to 96 hours of PST
treatment for the same number of cells to show characteristic signs of apoptosis.

110

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Over-all, we found that 1juM of PST effectively induced 90% of cancerous cells to
become apoptotic within 4 days of treatment in several cell lines.
»
5.2 Normal cells are not affected by Pancratistatin treatment
As previously discussed, another major problem with current therapies is
the non-specific nature of their action.

Here we demonstrate that the non-

cancerous counter-part cells given the same 1pM PST treatment are not
affected. Normal human fibroblast (NHF) cells were used as the counter-part to
the SHSY-5Y cells, do the unavailability of normal neuronal cells.

NHF cells

treated at the same concentration do not show signs of apoptosis, even after 96
hours of treatment.

The same phenomenon was seen in normal human

mammary epithelial cells (HMEC), normal mammary fibroblast (Hs578-Bst) cells,
and normal colon fibroblast (CCD-18Co) cells. We have also shown that PST
treatment does not affect the growth and proliferation of NHF cells that had been
treated for 48 hours, indicating that PST may be a safe and effective anti-cancer
therapy.

5.3 The growth of breast cancer cells does not recover following
Pancratistatin treatment
This study addressed a frequent problem with current cancer therapies:
any cancerous cells that survive anti-cancer treatments may have developed
resistance to that particular drug.

This is the main reason that multiple anti

cancer therapies are often used in conjunction with each other.
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In order to

evaluate

whether

cancerous

cells

could

recover

after

treatment

with

Pancratistatin, breast cancer (MCF-7) cells, which are notorious for developing
drug resistance, were treated for a short period of time (48 hours).

Even though

the majority of cells were still alive after this short PST treatment, the cells later
underwent apoptosis even after the PST was removed from the media and,
therefore, do not develop a resistance to the drug.

5.4 The non-genotoxic nature of PST
The observations of this study suggest the PST may be acting in a nongenotoxic manor. Many chemotherapeutic agents cause DNA damage in cancer
cells in order to induce apoptosis (Hui and Kavanagh 2003). One of the main
problems of these drugs is the non-specific nature of their genotoxicity - most
chemotherapies cause damage to normal cells which leads to side-effects and
secondary cancers (Boose and Stopper 2000). Here, we have shown that normal
cells treated with PST do not show two types of DNA damage: single and double
strand breaks, indicated by the comet and tunnel assays.

However, extensive

DNA damage (single and double strand breaks) can be observed in these normal
cells treated when they are treated with Taxol, a current anti-cancer drug.
Although further research is needed to rule out other types of DNA damage such
as point mutations or translocations, these results are further proof of the
exceptional specificity of PST.
In treated cancerous cells, the comet assay allowed for the observation
there was no single or double strand breaks during the early phases of apoptosis
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indicating that PST did not fragment DNA in order to induce apoptosis; rather,
DNA fragmentation seems to be a result of apoptotic nucleases. Indirectly, we
have shown thjat the target of PST in cancerous cells is not likely the DNA.
Previous research in our laboratory has shown that double strand DNA breaks
are not induced early on in PST-induced apoptosis in cancerous Jurkat (human
lymphocyte) cells (Kekre et at. 2005).

This is not true for the current therapy

options, VP16 and Taxol, which have universal targets that are found in both
cancerous and non-cancerous cells. These treatments target fast dividing cells,
thus cancer cells are most affected. However, there are normal, actively dividing
cells in our bodies that are also subject to damaging effects of chemotherapeutic
agents (Boose and Stopper 2000).
The high specificity of PST to induce apoptosis only in the cancerous cells
indicated that the target of PST may not be available for attack in these normal
cells and, therefore, PST does not cause any physiological impairment on the
growth of normal cells. Here we have shown that PST has a direct effect on the
mitochondria of cancerous cells.

In addition, there are no structural similarities

between PST and any known genotoxic agent (McNulty, unpublished work).
Taken together, these points indicate that PST might be targeting proteins and/or
factors, other than DNA damage, in order to induce apoptosis in cancerous cells.
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5.5 Mitochondria as the targets of Pancratistatin

Caspase-3 activation is associated with both the intrinsic and extrinsic
pathways of apoptosis.

Our results indicated that Pancratistatin treatment

activates caspase-3 in cancerous cells, but not in normal healthy cells. In this
study, we have observed that the inhibition of caspase-3 activity by DEVD-fmk
did not prevent Pancratistatin-induced apoptosis in cancerous cells.

These

results need to be confirmed using other indicators of apoptosis, such as
annexinV.

However, these results indicated that Pancratistatin may induce

caspase-3 independent apoptosis in cancerous cells. Because permeablization
of the mitochondria can lead to the release of AIF and the induction of caspase-3
independent apoptosis, the intrinsic mitochondrial pathway was the next obvious
focus of this investigation.
An increase in the amount of reactive oxygen species (ROS) has been
linked to mitochondrial dysfunction (Fleury et al. 2002). In the present work, we
have shown that an early and steady increase in ROS is induced when cancer
cells are treated with PST, while normal cells do not exhibit this increase. These
results lead to further investigation into the mitochondria as possible targets of
PST in cancerous cells.
The main metabolic function of the mitochondria is to produce energy for
the cell in the form of ATP. A decrease in total cellular ATP concentration can be
indicative of mitochondrial dysfunction (Orrenius 2004). The results of this study
have illustrated that cellular concentrations of ATP in cancerous cells decrease
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significantly early during PST treatment. Normal cells, on the other hand, do not
show any of these changes in the total cellular ATP concentrations.
While thp mitochondria of the cell is responsible for the production of
much of a cell’s energy, inside the mitochondria is held a slurry of pro-apoptotic
proteins. Mitochondrial membrane permeablization plays a key role in apoptosis
(Fernadez-Chenca 2003, Duchen 2004, Green and Reed 1998) by releasing
caspase activators such as cytochrome c, releasing caspase-independent death
effectors, and causing the loss of essential mitochondrial functions (Green and
Kroemer 2004, Yuan 2001).

Because the loss of mitochondrial membrane

potential alone can trigger apoptosis (Kroemer 2003), if Pancratistatin can induce
mitochondrial membrane permeablization by targeting a vulnerability specifically
in cancerous cells, the cells will have no choice but to undergo apoptosis.
Here we investigated the ability of PST to induce mitochondrial membrane
potential collapse specifically in cancerous cells. JC-1 and mitotracker red, two
dyes used to detect mitochondrial membrane potential (Olichon et al. 2003),
have been employed to clearly show that PST induces early mitochondrial
membrane permeablization in neuroblastoma, breast cancer, and colorectal
adenocarcinoma cells. This result was confirmed using the relatively new assay
called Mito-casp.
membrane

This assay also allowed us to confirm that mitochondrial

potential

collapse

takes

place

before

caspase

activation

in

Pancratistatin-induced apoptosis. Additionally, staining with JC-1 indicated that
the mitochondria of the normal counter-part cells are not affected by treatment
with PST.
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5.6 Isolated cancerous mitochondria treated with Pancratistatin show signs
of mitochondrial dysfunction
One of the most important and interesting outcomes of this study is that
isolated mitochondria from cancerous cell lines are susceptible to Pancratistatin
treatment. For the first time, we have shown that direct treatment of cancerous
mitochondria with PST causes mitochondrial dysfunction.

Furthermore, the

mitochondria isolated from the normal, healthy cells are not affected by similar
Pancratistatin treatments. The direct action of PST specifically on the isolated
mitochondria of cancer cells clearly demonstrates the ability of PST to specifically
target the mitochondria of cancer cells. If the mitochondria are the initial site of
PST’s action, why then are the mitochondria isolated from normal cells not
affected by treatment with PST?
Some current researchers have focused on the differences between the
mitochondria of cancerous versus normal cells (Don and Hogg 2004, Villa and
Doglia 2004). As previously discussed, many cancerous cells have an altered
metabolism, mitochondrial DNA mutations, altered membrane compositions, and
differences in the number, size, and shape of their mitochondria relative to their
normal counterparts (Green and Kroemer 2004, Villa and Doglia 2004, Sugiura et
al. 2004, Modica-Napolitano and Singh. 2002, Polyak et at. 1998).
In addition, a number of proteins that play a role in metabolism are part of
the mitochondrial permeability transition pore (PTP) and some of these proteins
may be involved in the metabolic alterations or other observed changes in the
mitochondrial of malignant cells. For example, several proteins are up or down-
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regulated or are only present in cancerous mitochondria: hexokinase and PBR
(peripheral

benzodiazepin

receptor),

both

involved

in

the

PTP

of

the

mitochondria, afe up-regulated in some cancerous cells (Modica-Napolitano and
Singh. 2002, 2004). In addition, deficiency or absence of the B subunit of F1ATPase has been observed (Modica-Napolitano and Singh. 2004).

Future

research into the mitochondrial target of Pancratistatin may unveil a specific
protein or other biochemical differences between cancerous and normal
mitochondria.
mitochondria

Here we have shown that direct treatment of cancerous
with

water-soluble

CoQ10 protected

these

organelles

from

mitochondrial dysfunction following PST treatment, indicating that PST and
C 0 Q 10 may share a similar binding site on or in the mitochondria. The differences
in malignant cells’ mitochondria may allow researchers to specifically target the
mitochondria of cancer cells using PST or other anti-cancer therapeutics and,
thus, induce apoptosis specifically in cancer.

5.7 Induction of apoptosis of cancerous cells treated with Pancratistatin is
BAX independent
The Bcl-2 family of proteins play a key roll in the intrinsic pathway of
apoptosis.

In particular, activation of the pro-apoptotic Bcl-2 protein BAX has

been found to be involved in the permeablization of the mitochondrial membrane
and possibly in the opening of the mitochondrial permeability transition pore
(Reed 2000). Here the possible role of BAX activation in Pancratistatin induced
apoptosis in cancerous cells was investigated using single domain anti-bodies
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against the BAX protein. Previous research in our laboratory has demonstrated
that these single domain anti-bodies can prevent oxidative stress induced
apoptosis in neuroblastoma cells (unpublished results).

However, these anti

bodies

apoptosis

could

not

prevent

Pancratistatin

neuroblastoma (SHSY-5Y) cells.

induced

in

these

Therefore, these results indicated that PST

may cause MMP independent of the BAX pathway and confirm that PST may
directly target the mitochondria.
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CHAPTER 6: CONCLUSIONS
The current study has demonstrated the novel anti-cancer potential of the
natural

compound

Pancratistatin

and

provided

insight

into the

possible

mechanism of apoptosis induced by this drug. Apoptosis was induced in several
cancerous cell lines following PST treatment at relatively low concentrations,
while normal healthy non-cancerous cells subjected to the same treatment, did
not show any signs of DNA damage or interference with cell division. Given the
high specificity of Pancratistatin to induce apoptosis only in cancerous cells, this
compound could become an important anti-cancer therapy.

Further study is needed to elucidate the exact mechanism by which
cancer cells undergo apoptosis following treatment with PST. Here it has been
revealed that the mitochondrial differences between cancerous and normal cells
may play a role in the specificity of Pancratistatin, precisely how has yet to be
unveiled. Our future work will focus on finding the cancer-specific mitochondrial
target of PST and investigating the in vivo effect of Pancratistatin.

This study has opened the doors for further study into the differences
between normal and cancer cells, which will provide new insight for possible
ways to combat cancer and leave patients relatively free of the current sideeffects.

These treatments may be PST, analogs or novel treatments that will

prey on these differences in order to selectively kill cancer.
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CHAPTER 7: FUTURE PROSPECTIVES
This study has shown that Pancratistatin can induce apoptosis specifically
in cancerous cells by targeting the mitochondria.

However, we must find how

PST is able to selectively target cancerous cells so effectively and further confirm
its efficacy.
The mitochondria of cancerous cells may have an available target that is
not accessible or possibly not even present in non-cancerous cells.

Further

studies will need to focus on finding the protein or lipid differences between the
mitochondria of cancerous versus normal mitochondria that may leave cancerous
mitochondria vulnerable to PST’s effects.

In addition, the possible differential

sensitivities of the PTP to PST will also need to be evaluated. To better
understand the precise target of PST, affinity chromatography using a PSTagarose bead conjugate and MALDI-MS with deuterated derivatives of the active
compound will lead to the isolation and identification of the specific proteins that
can interact with Pancratistatin.
In addition, an organic method for synthesizing of Pancratistatin is
being developed by our collaborator. Several derivatives, that have been shown
to

have

lower

anti-cancer

activity,

have

helped

determine

the

active

pharmacophore of PST (McNulty et al. 2005) and derivatives that make use of
this information are being developed.
Currently underway is an in vivo study of the efficacy of Pancratistatin.
Immuno-compromised or nude mice can be used to host xenographs of
cancerous human cell lines and these animal models are currently being used
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with several human cancer cell lines to further evaluate the anti-cancer potential
of Pancratistatin. The nude mice models will establish the capability of PST to
induce apoptosis in human tumors in vivo and allow for toxicological and
pharmacological studies to determine Pancratistatin’s stability in the mammalian
system and any pathological effects on other tissues including the heart, lungs,
kidneys and liver. Preliminary results indicate that Pancratistatin does not cause
any adverse effects in nude mice treated with Pancratistatin and that PST
treatment has slowed the growth of tumors in these animal models.
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